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1.1 CHARACTERISTICS OF HIV AND EPIDEMIOLOGICAL OVERVIEW 
The human immunodeficiency virus is an enveloped single strand positive-sense RNA virus with 
a diameter of 110 nm. It belongs to the subgroup of lentiviridae in the family of retroviridae (1). 
There are two major types of HIV: HIV-1 and HIV-2. HIV originally stems from the simian 
immunodeficiency virus (SIV) which is found especially in chimpanzees. HIV-1 was passed on to 
the human species from apes while HIV-2 descend from sooty mangabey monkeys (2).  
HIV-1 is divided in subgroups such as –M,-N,-O and –P. These subgroups are divided into 
subtypes. Group –M, the most pandemic subgroup, is composed of subtypes A to D, F to H and J 
to K (3). This high genetic variability is caused by the recombination and mutation of the reverse 
transcriptase (4), certainly one of the key-enzymes of HIV.  
At the beginning of the 21st century about 49% of all patients worldwide were diagnosed with 
subtype C. Subtypes A and B caused 12% and 11% of all global infections (4).   
In the year 2017 36.9 million people were globally infected with HIV, the infection rate was 2.1 
million, and 1.1 million deaths caused by HIV were documented. Recently only about 50% of all 
infected patients are undergoing therapy. The infection rate as well as the prevalence of HIV could 
likely be reduced if the remaining 50% (17 million) would undergo antiretroviral therapy, too (5). 
The Robert Koch Institute estimated the infection rate to be as high as 2700 patients at the end of 
2017 in Germany. It was estimated that 86,100 people were infected of which approximately 
11,400 were not diagnosed. Deaths related to HIV (450 in 2017) could be decreased if more 
infected individuals received treatment. Further a more effective HIV-therapy is highly desirable 
(6). 
An important factor is also the prevention of novel HIV infections as most HIV-positives are 
infected by unsafe sex practices. A greater knowledge about safe sex and its importance to prevent 
sexual transmitted diseases needs to be established worldwide (7). 
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1.2 INFECTION AND VIRUS REPLICATION 
In order to spread in the organism, HIV has to enter specific cells to replicate itself. As indicated 
above, semen and mucosal fluids are the main factors to pass HIV on. CD4+ T-cells, dendritic cells 
and macrophages are the commonly targeted cells also found in these fluids. Viral entry is mediated 
by fusion with the cell membrane. For this process the main cellular receptor glycoprotein CD4 as 
well as one of the chemokine co-receptors CCR5 or CXCR4 on the target cells are required (8) (9). 
The viral mediator for cell entrance is the surface glycoprotein gp120 together with gp41, a 
transmembrane protein. The viral tropism defines the strains. The T-tropic strain targets T cells and 
needs the chemokine co-receptor CXCR4 to enter a T cell. The M-tropic strain targets T cells and 
macrophages and uses CCR5 as co-receptor.  
  
Figure 1: HIV Strains and HIV entry. Three HIV tropisms are shown: the X4R5- mixed tropic virus, the X4-tropic 
and the R5-tropic virus. Once connected with the target cells the viral membrane fuses with the cell membrane 
and the viral load is transferred. 
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There are three kind of virus tropisms: R5-tropism, X4- tropism and dual X4R5-tropism where the 
virus is able to use both co-receptors (see Figure 1) (10).  R5-strains are typically observed in early 
infection stages (11)(12).  Later in the course of the disease a class switch from R5 strain to X4 
strain is possible (13).  
 
1.3 DELTA 32 DELETION 
About 10% of the northern European population carry a mutation on one CCR5 allele, the so called 
delta 32 mutation. Between the Baltic and the White Sea a frequency up to 15% is reported (14). 
Individuals with the delta 32 mutation hold a deletion of 32 bp, nt 554 to 585 in the open reading 
frame (ORF). The mutation is located in the CKR-5 allele on the short arm of chromosome 3. This 
deletion is located in a region which codes for the second extracellular loop of the chemokine co-
receptor (see Figure 2) The delta 32 mutation introduces a premature stop codon; instead of 352 
amino acids (aa) the truncated form has only 215 aa and therefore the CCR5 co-receptor cannot be 
transported to the cell surface. Individuals with this mutation show a delayed progression of 
infection if heterozygous. Moreover they are also immune to HIV R5 infection if homozygous for 
the mutation: it was shown that a group of people carrying the mutation and exposed to HIV were 




Figure 2: Schematic picture of the CCR5 co-receptor. The amino acids affected by the ∆32 mutation are high-
lighted in red in the second extracellular loop of the 7-transmembrane-domain-receptor. Graphic modified from 
Quillent et. al. (16) 
 
1.4 CLASSICAL HIV THERAPY 
The classical clinical approach for the treatment of HIV is the -active-retroviral therapy (ART). 
More than 25 antiretroviral drugs depending on 6 different mechanistic classes are frequently used.  
Some antiviral drugs are protease inhibitors (PIs) while others inhibit the proteolytic production of 
viral proteins fusion inhibitors (FIs) limit the viral invasion to human cells and integrase strand 
transfer inhibitors (INSTIs) minimize the number of viral DNA integrated to the human genome. 
Nucleosidic/nucleotidic reverse transcriptase inhibitors (NRTIs/NtRTIs) and non-nucleosidic 
reverse transcriptase inhibitors (NNRTIs) inhibit the reverse transcription of viral RNA directly to 
prevent the integration of viral genetic make-up into the human genome. CCR5-Inhibitors prohibit 
the entrance of HIV into its target cells. Finally there are additionally supportive drugs used to 
enhance the mechanisms listed above (17) (18). 
A big disadvantage of the traditional HIV therapy are the highly abundant side effects. Those are 
gastrointestinal symptoms such as diarrhea,  nausea and vomiting; but also severe side effects such 
as hepatotoxicity, depressions and suicidality (18). Additionally HIV infection cannot be cured by 
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ART. In fact, only the progression is delayed. The patient remain infected although the viral load 
can drop under detection limit. 
The first time a patient was declared healed from HIV was “the Berlin patient”. In February 2007 
an HIV positive patient suffering from a myeloid leukemia was transplanted with an allogenic 
haematopoetic stem cell graft by the team of G. Hütter at the Charité hospital in Berlin. For the 
allogenic transplantation (treatment of the myeloid leukemia) a matched donor homozygous for 
the ∆32 mutation was chosen, in order to treat the leukemia and render the patient resistant to HIV. 
After stopping ART on the first day of transplantation, the number of viral RNA-copies showed a 
long term suppression. Over the years the second main diagnostic marker, the CD4+ T cell surface 
marker, increased too (19). Usually proviral DNA can be still extracted from the blood and also 
from tissue of patients who show a long term remission. Under ART therapy reservoirs such as the 
rectum remain infected by the virus (20). The Berlin patient underwent numerous tests such as 
single copy assays, apheresis of large amounts of leukocytes from peripheral blood, 
microdissection of tissues, rectal-biopsy and monitoring of HIV antibodies (19) (21) (22). 
Nevertheless as of today, the Berlin patient remains virus free in terms of RNA copies as well as 
in terms of proviral DNA.  This approach - the only known curative treatment - is difficult to 
reproduce on the grounds that ∆32 homozygous donors are scarce: only about 1% of the Caucasian 
population is homozygous and secondly HLA-matching declines the number of potential donors 
for transplantation (19).  
 
1.5 GENOMIC ENGINEERING 
The key idea of genomic engineering is to modify the human genome. This modification can either 
be a deletion of nucleotides or an insertion of one or more new nucleotides. Both changes lead to 
a different genetic code. As many diseases result of only small mutations in the genetic code, 
genome engineering has great potential to remove those mutations and to provide a cure for 
hereditary as well as some infectious diseases. 
Genomic engineering was first attempted in 1988 with HO endonucleases in order to boost 
homologous repair in yeast. Endonucleases are enzymes that are able to cleave DNA at specific 
regions within the two strands. Today there are more specific and more efficient tools than HO 
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endonucleases. These tools can be designed and customized for any genetic region. The first of 
these tools were zinc-finger-nucleases (ZFN), followed by transcription-activator-like effector 
nucleases (TALEN) and lately CRISPR/Cas9 were established (23).  
Removing nucleotides leads to a gap in the DNA which would prevent further cell replication. To 
circumvent cell death, the cells can activate two repair mechanisms which can fix DNA breaks in 
the genome. These are the non-homologous end joining (NHEJ) and the homologous 
recombination (HR). Contrary to the HR, NHEJ does not restore the original information and leads 
to the introduction of small insertions or deletes nucleotides, called InDels. This repair pathway 
allows to knockout genes which are desired to be silenced. HR restores information relying on the 
sister chromatid. The redundancy of two identical chromatids prevents the cells from damage due 
to the lack of genetic information. HR can be used to insert new sequences while introducing a 
donor DNA template (24) (25).   
ZFN consist of 3-6 zinc-finger modules, each of which is able to recognize 3 nucleotides located 
at the target site. These modules are linked to a FokI domain which set the DNA break and works 
as a dimer. This type II restriction endonuclease was isolated from Flavobacterium okeanokiotes. 
Type II restriction enzymes cut DNA closely to their binding sequence. ZFN work as dimers, each 
unit binds one DNA strand. The binding is necessary for the Fok domains to dimerize and to set a 
double strand break (DSB) (see Figure 3) (26) (27).   
 
More simple in production, and also less cytotoxic than ZFN are TALEN. Additionally, TALEN 
are less active in terms of off-target activity if designed for the same sequences (28). Similar to 
ZFN, TALEN have to dimerize for successful cleavage. Each TALEN consist of a DNA binding 
Figure 3: Structure of ZFN. Two ZFNs dimerize to a functional complex. The binding domains built of three zinc-
finger modules are designed specifically for the desired locus.  
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domain, a TALE, that binds to a specific target site and which is linked to the FokI domain (see 
Figure 4) (25).  TALEs have been first discovered in 2006. These effector protein are used by 
Xanthomonas to overtake the transcriptional machinery of rice plants. They mimick the plants 
transcriptional factors and facilitate the bacterial infection (29). In 2009 Boch et al. managed to 
make TAL-III effectors useful for biotechnological purposes. By understanding the genetic code 
of these proteins they established the knowledge how to design TALEs for specific DNA targeting. 
The DNA recognition boxes of TALEs in Xanthomonas consist a span of 15.5 to 19.5 repeat 
domains, while most of them contain 17.5 repeats. A di-amino acid motif on position 12 and 13 
interacts directly with DNA bases and is crucial for the sufficient binding of the protein. 
Nevertheless each repeat corresponds to a certain nucleotide. Due to this mechanism the TALENs’ 
binding domain is very specific to its individual DNA locus (30). 
 
Figure 4: Structure of TALEN. Left and right arm bind to their specific target sequences. Simultaneously the FokI 
domains dimerize and create a DSB. The binding domain consists of 19 repeat domains with each of them binding 
to one nucleotide. 
With ZFN about 50% of CCR5 disruption can be realized. Perez et al. showed that genetically 
modified T-cells have a relative survival advantage in contrast to native T-cells whilst challenging 
with CCR5-tropic HIV-1 in vitro (31). Pablo Tebas et al. showed already in a first clinical study 
that the gene therapy with ZFN of patients with aviremic HIV infection showed some  functionality 
while reducing the viral load under ART interruption (although the effect was limited)  but also 
safe (32). 
E. Meyer in the Cornu Lab showed that using TALEN the cleavage efficiency in CD34+ stem cells 
derived from cord blood reaches up to nearly 90% on the CCR5 locus. Meyer demonstrated that 
off-target effects on CCR2, which is a locus highly similar to CCR5, were below background, 
whereas in the ZFN setting the off-target on the CCR2 locus were significant (33).  
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In the present study, the used pair of TALEN bind and cleave directly beyond the sequence coding 
for N-terminus of the CCR5 protein. The region located in this area containing several tyrosine is 
known to be crucial for HIV binding into the target cells (34).  The disruption of this important part 
of CCR5 should prevent HIV from entering and the chances to create HIV resistant cells are 
increased. 
 
1.6  T CELL DEVELOPMENT  
T cell development in-vivo. 
Different premature T cells develop from the common lymphoid progenitor. These premature T 
cells migrate from the bone marrow to the thymus where differentiation takes place. In-vivo the 
process of differentiation takes three to four weeks (see Figure 5).  Lymphopoetic stem cells in the 
thymus are called thymocytes or thymus-dependent T-lymphocytes. After differentiation the cells 
undergo a stage of high proliferation. Ligands interacting with Notch 1 receptor and IL-7 then drive 
the thymocytes towards the T cell lineage. At the beginning the CD4- /CD8-, so called double 
negative thymocytes (DN), are generated. The DN rearrange their T cell receptor genes during the 
β-selection. A broad variability of different T cells is created in order to defend the organism 
against a maximum number of different pathogens. Thymocytes that have not rearranged the TCR 
β-chain undergo apoptosis (35).  
A minority of these precursor T cell will be part of the γδ-lineage whilst the majority will become 
part of the αβ-lineage. As the expressed Pre-T cell receptor and CD3 build a complex the T cell 
precursors are now CD3+. The γδ-T cells remain CD4- and CD8- (but CD3+) and they are 
immediately exported to the periphery.  αβ-T cells migrate to the thymic cortex where they become 
CD4+ and CD8+ double positive cells and subsequently move back to the medulla.  
The early T cell receptor is able to recognize self-antigens presented on MHC molecules by the 
thymic epithelium. Selections guarantee that the mature T cells will be able to efficiently defeat a 
wide array of pathogens while not attacking cells from the own organism. First the cells undergo a 
positive selection; they slightly bind the MHC molecules and receive a “surviving signal” - all cells 
which bind too strongly or too weakly do not survive. In the second selection process, a negative 
selection, thymocytes that bind too strongly on self-antigens undergo apoptosis. The remaining 
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cells either become CD4+ or CD8+ single positive depending on their interaction with MHC-I or 
MHC-II and they are sent as mature T cells to the periphery (35,36).  
 
Figure 5: Schematic view of the differentiation process of T cells in-vivo. Common lymphoid progenitor (CLP) cells 
differentiate into premature T cells. These cells migrate from the bone marrow to the thymic medulla where they 
differentiate under the influence of IL-7 and Notch ligands further and finally undergo β-selection. DN cells which 
are not able to rearrange their TCR β -chain die. γδ-T cells are immediately exported to the periphery while αβ-T 
cells move to the cortex. After reaching a CD4+8+ double positive state they lose one of these trades, move back to 
the medulla and then undergo a second process of selection. At the end of differentiation mature T cells either CD4+ 
or CD8+ are exported to the periphery. Graphic modified from Janeway’s Immunology (35).  
 
T cell development in-vitro. 
Haematopoietic stem cells (HSC) are multipotent. Both the myeloid as well as the lymphoid cell 
lineage develop from HSCs. These stem cells are CD34+ and can be easily identified by their CD 
markers. Apart from the bone marrow, the umbilical cord can be used as a source of CD34+ stem 
cells, too. Contrary to the extraction from bone marrow, the preparation of HSCs from cord blood 
is less complex and also entails no risks or discomfort for the donor. CD34+ stem cells from cord 
blood are perfectly suitable for the in-vitro differentiation of T cells.  (37) 
The thymus stroma is absent in an in-vitro cell culture setting. OP9-DL1 cells are stromal cells 
which derive from the bone-marrow. This cell line ectopically expresses the delta-like-1 ligand 
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which is essential for the Notch signalling pathway (38). OP9-DL1 cells are used as feeder cells 
and are co-cultured with the T cell precursors to mimic the thymic tissue. Mammals have four 
different notch receptors. Ligands binding to these receptors are either from the Delta or from the 
Jagged/Serrate family. The receptors consist of a large type I transmembrane protein. By 
proteolytic conformational change of the intracellular receptor part an active form is created as 
soon as a ligand binds to the extracellular part. The whole receptor is translocated to the nucleus 
where it influences CBF1/RBP-JK which is a transcriptional repressor (39) (40). Notch signalling 
has influence on many different cell types. In haematopoietic cells during haematopoiesis this 
pathway drives proliferation rather than differentiation. In lymphoid progenitors Notch prevents 
B-Cell differentiation and strongly supports T cell development (41). 
Apart from Notch signalling, IL-7 has to be supplemented to the T cells. IL-7 is known as an 
important cytokine for differentiation of the lymphoid lineage such as for example natural killer 
cells (42). Hübner et al. have successfully used this ligand for T cell differentiation (43). 
Even before T cell receptor-up-regulation, the cells become sensitive to IL-2 which promotes 
further proliferation. It is known to be the most important cytokine in terms of T cell proliferation 
(35). Therefore IL-2 should be added to the cells as soon as double positive (DP) cells are detected. 
The different subsets of premature T cells can be pinpointed via flow cytometry. The cluster of 
differentiation (CD) markers are up- and downregulated depending on the differentiation stages of 
the premature T cells. There are four stages that can be described: early T cell progenitors (ETP), 
T cell progenitors (pro T cells), premature T cells (pre T cells) and immature single positive T cells 
(ISP). With the help of the CD markers the stage of each T cell progenitors can be determined. 
Table 1 describes the phenotypes of T cell precursors. ETPs express CD34+ on their surface, but 
not yet CD7. Neither CD1α nor CD5 can be found. Pro T cells in contrast already express CD7 
while CD34 can still be detected on their surface. Although they are negative for CD1α, their CD5 
status is positive. Double positive in terms of CD1α and CD5 are found in pre T cells which keep 
this phenotype as they become ISP or double positive (CD4/CD8) cells. Their CD34 status is 
negative, but CD7 is highly expressed. ISP and DP are negative for CD34, but low positive for 




 ETP Pro T cells Pre T cells ISP/DP 
CD34 + + - - 
CD7 - + + low 
CD5 - + + + 
CD1α - - + + 
CD4 - - - +/- 
CD8 - - - +/- 
 
Table 1: Phenotype of the four different T cell progenitor subsets. 
 
1.7 MONOCYTE/ MACROPHAGE DEVELOPMENT  
Monocyte development in vivo 
Monocytes spend about 12-24 hours in the blood stream until they migrate to different types of 
tissue. In the tissue monocytes differentiate further to macrophages; the “scavengers” (phagocytes) 
of the immune systems. Phagocytes opsonize pathogens and cell debris: pathogens are incorporated 
into the cells and then neutralized via digestion.  Furthermore, macrophages release cytokines 
which activate other leucocytes and enhance inflammation. Macrophages play an essential role in 
both the innate immune response and the subsequent adaptive immune response (35,36). 
Stem cells in the bone marrow differentiate firstly in common myeloid progenitors and then later 
into monoblasts and premonocytes. This process is mainly triggered by a cytokine called 
macrophage colony stimulating factor (M-CSF). Additionally, IL-3 secreted by TH1 cells promotes 
the macrophage evolution too.  The complete differentiation in adult monocytes lasts only two days 
in-vivo (see Figure 6) (26, 27). 
Adult monocytes express CD14 on their surface. CD14 can be detected on 40-65% of all monocytes 
and can be considered as a general marker. Additionally to CD14, CD16 can be expressed too. 
Generally two subsets of monocytes can be distinguished: CD16- and CD16+ monocytes which 
have a lower anti-inflammatory potential. In conclusion, CD16 is not highly distinctive for 
monocytes in general, but defining for subsets of these cells (46). 
CD33 is a marker found on osteoclasts and monocytes. Taken alone it is not specific for monocytes, 
but in combination with CD14, CD33 becomes specific for mononuclear cells. The reason for this 
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is that osteoclasts are merged cells, so called syncytia. After merging, the “new” cell loses CD14 
and the marker can no longer be detected on the surface. A combinatory detection of CD14 and 
CD33 is therefore a valid assay to proof the presence of monocytes or macrophages (which as well 
show co-expression of CD14/CD33) (47). 
 
 
Monocyte development in vitro 
In-vitro differentiation of CD34+ cord blood derived cells to monocytes/macrophages requires two 
cytokines: M-CSF and IL-3. M-CSF is found to promote the differentiation from precursor cells 
into CD14+ macrophages, but inhibits dendritic cell development.  The inhibitory effect on 
dendritic cell differentiation cannot be reversed anymore after only 12 days of M-CSF influence 
on myeloid precursor cells (48). IL-3 allows the differentiation of monocytes into macrophages. In 
contrast to M-CSF, a medium containing IL-3 alone is capable of generating dendritic cells. In 
cultures containing M-CSF and IL-3 both cytokines work synergistic on macrophage 
differentiation. This condition has, however, not the potential to differentiate dendritic cells (49). 
Figure 6: Schematic view of the differentiation process of monocytes in-vivo. Common myeloid progenitor (CMP) 
cells differentiate into monoblasts. Under the influence of IL-3 secreted from TH1 cells and M-CSF monoblasts 
differentiate into premonocytes and then into monocytes. Once migrated to the tissue the monocytes finally become 






2.1 PROJECT GOALS 
Ideally, targeting CCR5 in CD34+ stem cells would be a “single shot” treatment that causes lifelong 
protection against HIV R5 tropic strains. If engrafted in the patient, the differentiated target cells 
would have a survival advantage to the unmodified equivalents. The patient would enrich in-vivo 
HIV resistant cells, because the HIV susceptible cells will be slowly eliminated by the virus. The 
fundament of the HIV infection was destructed in this way: all target cells, in particular CD4+ cells 
such as macrophages and T cells, could no longer be infected with R5 tropic strain. This highly 
innovative therapy concept is the aim at the Institute for Transfusion Medicine and Gene Therapy. 
A Phase I/II clinical trial is planned and will be carried out soon.  
Therefore, I want to demonstrate in our proof of concept and pre-clinical validations that 
genetically modified human stem cells can develop normally in the preferential HIV target cells: 
T cell precursors as well as monocytes and pre-stage macrophages. The cells need to go through 
all differentiation stages found during physiological cell development as indicated above. 
Furthermore, in unedited samples, I will be monitoring the expression of CCR5 during T cells and 
monocytes differentiation. This will give an indication in which stage the CCR5 co-receptor 
emerges in the differentiation process. Also, the earliest stages for an HIV infection of T-cells and 
monocytes will be determined. Finally CCR5 expression level needs to remain repressed after 
successfully disrupting the CCR5 gene on the genomic level. 
For a clinical approach more data is necessary to be sure that ex-vivo modified cells can undergo 
the normal differentiation process when they are back in vivo. 
In the beginning of this thesis, general protocols for the differentiation from CD34+ stem cells 
derived from cord-blood to monocytes/macrophages and T cells will be established. After setting 
up a protocol for in vitro differentiation, TALEN treated stem cells are expected to undergo the 
same process of differentiation as untreated cells. Both treated and untreated cells are then 
compared and the potential of TALEN treated cells to become mature cells can be evaluated. The 
immature cells are analysed on their genotype via molecular biologic methods in the course of 
differentiation. Additionally to the genotype, their phenotype is determined via flow cytometry 
during the whole process.  
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MATERIAL AND METHODS 
 
3.1 LINEARIZATION OF DNA PLASMIDS FOR MRNA PRODUCTION 
For the mRNA production linearized plasmids were required. TALEN need to dimerize at the target 
side so a “left” and a “right” protein is needed. The two plasmids that were used for translation are 
#1539 and #1540. 
Both plasmids contain a T7 promoter for the T7 RNA polymerase which is used for mRNA 
production. After the T7 promoter, the transcription start and the open reading frame (ORF) of the 
TAL effector DNA binding domain are coded and the FokI cleavage domain follows at the C-
terminus. 
Plasmid #1539 and #1540 were provided by Cellectis, Paris in the frame of a collaboration. 
For the linearization, 10µg of one plasmid was incubated at 37°C for 2 hours together with 2µl 
Hind III HF (NEB, Germany) and 5µl Cutsmart buffer (NEB, Germany). The solution was filled 
up to 50µl with RNAse free water (Ambion). 
For experimental control, the linearized plasmids were loaded on a 1% agarose gel (see formula 
below). 
 
3.2 DNA PURIFICATION 
Purification of the linearized plasmids was carried out with the QIAquick ® Gel Extraction Kit 
(Qiagen, Germany). The DNA was combined with 5 volumes of PB buffer, further the sample was 
transferred to the column form the Kit. The first round of centrifugation was at carried out at 
17.000xg for 1 minute at room temperature.  
After this first centrifugation the columns were washed witch 750µl PE buffer. Another two rounds 
of centrifugation were performed.  
For elution 30µl nuclease-free water (ThermoFisher Scientific, Germany) was incubated for 5min 
on the column and then finally centrifuged.  
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DNA concentrations were determined via Nanodop 1000 spectrophotometer (ThermoFisher 
Scientific, Germany) 
 
3.3 DNA AGAROSE GEL ELECTROPHORESIS 
For all DNA loaded gels 1g ultrapure agarose (Serva Electrophoresis GmbH, Germany) was 
dissolved in 100ml TAE buffer 1X (1% agarose gel). Agarose melting was performed in a 
microwave. Before pouring the gel, 4µl of 10mg/ml ethidium bromide (Roth, Germany) was added 
to the solution. 
For a proper evaluation a size marker: 2-log DNA-ladder (NEB, Germany) was run along with the 
samples. The voltage used was in the range of 140 and 120 V for 20-30min.  
5µl of each sample was combined with 2µl of 10x orange loading-dye (Carl Roth, Karlsruhe, 
Germany) and filled up with ultra-purified H2O (Biochrom AG, Germany) to 12µl total. Optical 
analysis was performed with FUSION Fx Vilber Lourmat device (Peqlab, Germany). 
 
3.4 IN VITRO MRNA PRODUCTION 
To avoid RNA degradation, it is highly necessary to remove all RNAse molecules from the surface 
of all instruments used. Therefor mRNA production of the two Talen was performed in a special 
dedicated RNA-hood which was, together with all instruments (e.g. pipettes), carefully cleaned 
with RNAse Zap (Sigma-Aldrich, Germany).  
The protocol from the mMESSAGE mMACHINE® T7 Ultra kit (ThermoFisher Scientific, 
Germany) was followed for the transcription and also for the in vitro poly-A tailing reaction. 
The procedure started with mixing 10μl T7 2x NTP/ARCA, 2μl 10x T7 reaction buffer and 2μl T7 
RNA polymerase together with 1µg of purified linearized DNA to a total volume of 20μl. 
Incubation was performed at 37°C for 2 h. 
After the transcription reaction, the DNA template was digested with 1μl TURBO DNase at 37°C 
for 15min. The tailing reaction was carried out by mixing 20μl 5X E-PAP buffer, 10μl MnCl2, 
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10μl ATP solution, 36μl nuclease-free water and 2μl E-PAP. After an incubation time of 40min at 
37°C, the samples were placed on ice. 
A recovery step by adding 50μl 7.5 M lithium chloride, 50mM EDTA was performed at -20°C for 
30min. After centrifugation at 17.000xg at 4°C for 15min, the supernatant was removed and the 
RNA pellet was washed with 1ml 70% ethanol (Sigma-Aldrich, Germany). The centrifugation 
steps were repeated until all ethanol was removed by pipetting.  
Finally the mRNA was resuspended in 11μl of RNAse free water (ThermoFisher Scientific, 
Germany). All aliquots were stored at -80°C. 
RNA concentrations were determined via Nanodop 1000 spectrophotometer (ThermoFisher 
Scientific, Germany). 
 
3.5 RNA GEL ELECTROPHORESIS 
For evaluation of the RNA production, the mRNA was loaded on a denaturing formalehyde gel. 
The tailed RNA is expected to be relatively shifted in size compared with the simply transcribed 
form.  
Before setting up the gel all surfaces and gel chambers were carefully cleaned with RNAse Zap 
(Sigma-Aldrich, Germany) and DEPC water (see 3.22). For the RNA-gel, 1g of agarose Serva for 
DNA electrophoresis (Serva GmbH, Germany) was melted in 75ml DEPEC water while heated in 
the microwave. As soon as all agarose had been dissolved, the solution was cooled to 60 °C and 
10ml 10x MOPS (ThermoFisher Scientific, Germany) together with 18ml formaldehyde (Sigma 
Aldrich, Germany) were added. The whole solution was poured under a fume hood gently mixed 
into the tray where it polymerized. 
For experimental control 500ng of polyadenylated mRNA was incubated with 8μl RNA loading-
dye (NEB, Germany) and 1μl 200 μg/ml ethidium-bromide at 70°C for 5min. The same procedure 
was applied to 2μl of the mRNA sample before tailing. As sizemarker ssRNA ladder (NEB, 
Germany) was carried along next to the samples. 




3.6 GENOMIC DNA EXTRACTION 
QIAmp® DNA blood mini kit, (Qiagen, Germany) was used for gDNA extraction of the cultivated 
cells. The cells were either frozen as a pellet or used fresh for the extraction. The minimum amout 
of cells for this method was one confluent well of a 96-well plate (Sarstedt, Germany) while the 
maximum a cell number was 5x106 cells. 
The pellet was resuspended in 200μl PBS (PAN Biotech, Germany) and lysed with 4μl RNAse, 
200μl buffer AL and 20μl Protese (Qiagen, Germany) were added ant incubated at 56°C for 10min.  
After lysis, 200μl ethanol (Sigma-Aldrich, Germany) were added. The sample was transferred in a 
column and centrifuged at 6200xg for 1min. The filtrate was collected in a clean 2ml collection 
tube (Qiagen, Germany) which was replaced after each centrifugation. 
After centrifugation, the column was washed with 500μl buffer AW1 and centrifuged again at 
6200xg for 1min, 700µl washing buffer AW2 was used and the centrifugation was performed at 
maximum speed for 3min. In order to remove all residual ethanol, centrifugation at maximum speed 
was repeated for one more minute.  
 
#1539 
tailed RNA non tailed RNA 
#1539 
300 ng mRNA 
#1540 #1540 
Figure 7: Example of a RNA agarose electrophoresis. 300ng mRNA were loaded either after PolyA-tailing 
(tailed RNA) or before (non-tailed RNA). The mRNA of the TALEN left subunit as well as the right subunit 
are shown (#1539/ #1540). 
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Elution of the DNA was carried out with 30μl ultra purified water (Biochrom AG, Germany). 
Before spinning at 6200xg for 1min, the column was incubated with the water for 5min to increase 
yield. 
DNA concentrations were determined via Nanodop 1000 spectrophotometer (Thermo Fisher 
Scientific, Germany). 
 
3.7 DIRECT CELL LYSIS OF LOW COUNT CELL SAMPLES 
When the amount of cells did not reach a confluent 96 well, another protocol for gDNA extraction 
was chosen. 
The cell pellet was mixed with 0,4μl 20mg/ml Proteinase K (Peqlab, Germany) and 19.6μl 
DirectPCR Lysis reagent (Peqlab, Germany), transferred to a PCR tube, vortexed and spinned 
down. Incubation was carried out in a thermocycler (Biometra, Germany) at 56°C for 1 h. and 
45min at 85°C min to inactivate Proteinase K. After centrifugation, the supernatant was carefully 
harvested and transferred to a fresh Eppendorf tube. 
 
3.8 POLYMERASE CHAIN REACTION 
For amplification of the CCR5 locus and successful testing of genomic knockout - a special kind 
of PCR was used. In this “Touchdown” PCR the initial annealing temperature was higher than 
actual temperature required for the primers. With each cycle, the annealing temperature dropped 
by 1°C until the specific temperature for the primers was reached. Melting temperature is kept the 
same for all cycles. By following this PCR protocol the amplification of unwanted side products 
was decreased dramatically (50) (Table 4).  
For the PCRs, Phusion HF polymerase (NEB, Germany), 5xPhusion HF Buffer (NEB, Germany) 
and dNTPs (NEB, Germany) were used (see Table 3). The primers were ordered from Apara 
Bioscience (Freiburg, Germany) (see Table 2).   
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 Primer ID Sequence 5’  3’ 
TALEN 1 #1809 CAGTAGCTCTAACAGGTTGGACC 
TALEN 2 #1820 CACTATGCTGCCGCCC 
 
Table 2: PCR Primer for Touchdown PCR (33). 
 
 Substance Amount per reaction 
 Primer #1809 (10µM) 0,8µl 
 Primer #1820 (10µM) 0,8µl 
 dNTPS 8 (40mM) 1µl 
 5X Phusion HF Buffer 10µl 
 Phusion (2000 u/ml) 0,35µl 
 gDNA 100ng 
 H2O Xµl 
 ∑ 50µl 
 
Table 3: Ingredients of Touchdown PCR (33). 
 
 Step Temperature Time Go To Loops △T 
 1 98°C 180s    
 2 98°C 10s    
 3 72°C 30s   -1°C 
 4 72°C 13s 2 5  
 5 98°C 10s    
 6 66,6°C 30s    
 7 72°C 13s 5 33  
 8 72°C 420s    
 9 10°C hold    
 
Table 4: Program of Touchdown PCR (33). 
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3.9 T7 ENDONUCLEASE 1 ASSAY 
The T7 Assay was used to evaluate the genomic knockout of CCR5 by TALEN. The principle of 
this sensitive method is based on the particular properties of the T7E1 endonuclease. This enzyme 
recognizes single strand loops that form because of mismatches while denaturing and reannealing 
of the cleaved DNA fragments (see Figure 8) (51). InDel frequencies can be detected in the range 
of 5 to 95%. The cleavage by the T7 endonuclease is monitored on a 2% agarose gel. As positive 
control for this Assay HEK293T gDNA is used. This cell line has two CCR5 wildtype copies and 
one copy of the CCR5∆32 locus.  
Figure 8: Scheme of T7 Endonuclease 1 assay. The DSBs which are induced by TALEN are repaired via NHEJ. 
The target locus is amplified by PCR, the amplicon is then melted and reannealed. When a wildtype and an edited 
strand reanneal a heteroduplex is formed. This heteroduplex formation is recognized and cleaved by the T7 enzyme. 
The successful cleavage can be monitored on a 2% agarose gel. 
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In the first step 25μl of purified PCR product are denatured in 3μl 10x NEB2 buffer (NEB, 
Germany) at 95°C for 5min. The following reannealing is performed by turning off the heating 
block. The samples cool down slowly to room temperature. After 3 h the actual T7 reaction can be 
started. For this, 200 ng of DNA are filled up to 13.5μl with 1x NEB2 buffer (NEB, Germany). 
Together with 0.75μl of T7endonuclease the reaction is digested for 20min in a 37°C water bath. 
The digestion is stopped by adding 3μl 10x orange dye (Carl Roth, Karlsruhe, Germany) and placed 
on ice. The result is evaluated on a 2% agarose gel which is run for 30min at 130 V.  
 
3.10 T7E1-ASSAY EVALUATION 
The 2% agarose gel was captured with a FUSION Fx Vilber Lourmat device (Peqlab, Germany). 
A .jpeg file was exported and analyzed with ImageJ (NIH). ImageJ was used to perform a digital 
quantification of the uncleaved band, cleaved band#1 and cleaved band #2 (see Figure 8). With the 
following formula the percentage of cleavage was calculated: 
% 𝑜𝑓 𝑐𝑙𝑒𝑎𝑣𝑎𝑔𝑒 =
"cleaved band#1" + "cleaved band#2"
("unleaved band" + "cleaved band#1" + "cleaved band#2")
∗ 100 
 
3.11 CD34+ PREACTIVATION  BEFORE NUCLEOFECTION 
Two days before the nucleofection was carried out, CD34+ cells were thawed and cultivated. The 
desired number of stem cells was thawed at 37°C in a water bath until barely any ice was visible. 
The cyrotube was slightly shaken by hand in the water bath. The cells were transferred into a 15ml 
tube (Greiner Bio One, Austria) in which they were carefully mixed by adding dropwise 1ml of 
prewarmed X-vivo 15 Media (Lonza, Switzerland). In order to mix the fluids the tube was gently 
flicked with a finger. Finally the tube was filled up to 15ml with warmed medium.  The cells were 
now centrifuged at 300xg for 5min.  
After removing the whole supernatant the remaining cell pellet was suspended in X Vivo 15 plus 
supplements. The amount of final medium was chosen according to a final concentration of 
500,000 cells per ml (the cells were counted as described in chapter Cell counting3.18). 250,000 





The transfer of mRNA into the cells was performed with a 4D-NucleofectorTM (Lonza, 
Switzerland).  After counting the cells (see 3.18) the 100,000 cells/samples was pelleted (300xg 
for 5min) and the supernatant was discarded.  The nucleofection medium was prepared using the 
P3 Primary Cell NucleofectorTM Kit (Lonza, Switzerland) by mixing 3.6µl of “Supplement” 
solution and 16.4µl “NucleofectorTM Solution” per sample. The cells were resuspended in 20µl of 
the nucleofection mix, transferred to a 20µl NucleocuevetteTM and then either 6µg of TALEN (3µg 
left TALEN + 3µg right TALEN) mRNA or 2µg of green fluorescence protein (GFP) mRNA were 
added to the mix. GFP mRNA was used to monitor transfer efficiency. The program used was DZ-
100.  
Directly after the nucleofection the samples were transferred to a non-adherent 96-well plate 
(Sartstedt, Germany) which already containeded 80µl of prewarmed medium. The medium was 
chosen accordingly to the cell type to be cultivated: cultivation of T cells, monocytes or CD34+ 
cells. The samples were nucleofected one by one in order to minimize the time period of potential 
degeneration of the mRNA.  
The 96-well plates were kept 24h at 32°C and 5% CO2. This transient cold shock is known to 
increase the cleavage activity of TALEN. Originally Doyon et. al showed this fact with Zinc-
Finger-Nucleases (ZNF) in slightly different conditions. However Emily Meyer who had been in 
AG Cornu before me, had already proven that the concept is valid for TALEN and the setup 
described above, too  (52) (33).  
All untreated samples were neither in contact with nucleofection solution nor did they receive a 
pulse like the treated ones. One day after nucleofection the cells expressing GFP could be analysed 




3.13 MAINTENANCE OF OP9-DL1  
OP9-DL1 cells were kept on α-Minimum essential medium (α-MEM). 5g of α-MEM powder 
(Gibco Life Technologies, USA) were dissolved in 485.4ml ultra-purified H2O (Biochrom AG, 
Berlin, Germany) and 14,6ml 7.5% sodium bicarbonate (Gibco Life Technologies, USA) were 
added. The solution was filtered through a 0.22µm bottle top filter (Corning, USA). Storage time 
for this stock solution was max. 2-3 weeks at 4 °C. 
To complete the medium 195ml of the stock solution were combined with 50ml HyClone Defined 
Fetal Bovine Serum (FBS) OP9-FCS (GE Healthcare Ltd, UK) to a final concentration of 20% as 
well as with 2.5ml P/S (Sigma-Aldrich, USA) and 2.5ml L-Glutamine (GE Healthcare Ltd., UK.).  
Cultivation: for the T cell differentiation OP9-DL1 cells were used as feeder cells. OP9-DL1 were 
cultivated in a T-75 flask (Sarstedt, Germany) at 37 °C in an incubator (Heracell 240i, Thermo 
Fisher Scientific, Waltham, MA, USA) with 5% CO2 and splitted every 3 days.  
To split the cells, the medium was removed, the cells were washed with 10ml PBS buffer (PAN 
Biotech, Germany) and then incubated with 1.5ml Trypsin-EDTA (10x) (Germany) at 37 °C for 
5min. After detaching, 8.5ml of complete medium was added to the cells, the cells were collected 
and centrifuged at 2336xg for 5min. The supernatant was removed and the cells were resuspended 
in 1ml of complete medium in order to count the cells.  
The cells were then seeded at a density of 250,000 cells in 15ml complete medium and transferred 
to a T75–flask (Sarstedt, Germany). 
Two days before starting the T cell differentiation, a 6-well plate per sample with 50,000 OP9-DL1 
cells in 1ml complete medium was prepared. Alternatively, one day before differentiation 100,000 
OP9-DL1 cells could be seeded as well.  
 
3.14 CULTIVATION OF CD34+ CELLS 
The freshly thawed CD34+ cells were counted with NucleoCounter (ChemoMetec, Denmark). For 




CD34+ cells were cultivated in X-Vivo 15 (Lonza, Switzerland) without antibiotics. Due to this 
fact the medium was filtered through a 0.22µm filter (Merck Millipore Ltd., Germany) as an extra 
precaution to avoid any contaminations after supplementing with the cytokine cocktail. As 
supplements 25ng/ml rhSCF (ImmunoTools, Germany), 50ng/ml rhTPO (ImmunoTools, 
Germany), and 50ng/ml rhFLT3 (ImmunoTools, Germany) were added to the medium. 
Whenever CD34+ cells were not used for any nucleofections, 20ng/ml IL-3 (ImmunoTools, 
Germany) and 20ng/ml IL-6 (ImmunoTools, Germany) were supplemented in order to boost 
proliferation. 
 
3.15 DIFFERENTIATION OF CD34+ CELLS TO MONOCYTES 
100,000 CD34+ cells were transferred to a 24-well plate (Sarstedt, Germany) in 500µl of three 
different differentiation media.  500µl α-MEM (protocol 3.13) for each well was supplemented 
with 50ng/ml M-CSF (Immunotools, Germany) or 25ng/ml IL-3 (Immunotools, Germany) or both 
in combination. The cells were kept in the adherent 24-well plate till the wells were confluent, 
which could last up to 10 days, depending on the donor and also the medium selected. Then, the 
cells were transferred to an adherent 6-well plate (Sarstedt, Germany) where 1ml of each 
differentiation media was added.  
At every harvesting the medium was completely exchanged. Fresh medium was added whenever 
the pH-indicator strongly changed colour. The medium and cells were visually checked every 
second day. 
Splitting and harvesting: the cells were transferred to a 50ml falcon (Greiner Bio one, Austria). 
Afterwards the wells were washed with 1ml PBS buffer (PAN Biotech, Germany). The cells that 
remained on the bottom of the well were harvested using a cell scraper S (TPP, Switzerland).  
Scraping was performed in 800µl PBS. The scraper and the well were rinsed with 1ml PBS. The 
well was then first rinsed with 5ml PBS and afterwards one more time with 10ml PBS. 
The whole falcon was centrifuged 7min at 300xg at 14 °C. After removing the whole supernatant, 
the cells were resuspended in 1ml complete medium and then counted as described below. After 
taking the required number of cells for flow-cytometry analysis the rest of the cells were reseeded 
preferentially with a density of 50,000 in a 24-well plate. 
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3.16 DIFFERENTIATION OF CD34+ CELLS TO T CELLS 
T cells were co-cultured with OP9-DL1 cells. On adherent 6-well plates (Sarstedt, Germany) OP9-
DL1 cells were seeded 1-2 days before transferring CD34+ cells, as described above. Addition of 
300,000 CD34 cells on the already colonized dish was carried out dropwise and very carefully to 
not disturb the layer of feeder cells. 
In the first week 1ng/ml rh-IL7 (Immunotools, Germany), 2ng/ml rh-SCF (Immunotools, 
Germany) and 2ng/ml rh-Flt3 (Immunotools, Germany) were added to the complete -MEM-
media. From the second week onwards, rh-SCF and rh-Flt3 were removed. 
The volume was kept at 2ml total and fresh medium was added every week at the harvesting and 
flow cytometry analysis time-points. After the flow cytometry analysis the following cytokine 
cocktail was used: If CD7 expression was extremely high, IL-7 was removed (105 fluorescence 
units in the flow cytometry analysis). For high CD7 expression IL-7 was reduced to 0,5ng/ml (104-
105) and for low CD7 (max. 104) IL-7 was kept at to 1ng/ml. As soon as CD4/CD8 double positive 
cells are detected, 2ng/ml IL-2 should be supplemented to increase the amount of this population. 
 
3.17 HARVESTING OF T CELLS 
All cells were filtered through a 70µm cell strainer (BD, USA) into a 50ml falcon (Greiner Bio-
one, Austria). This filtration was performed to remove OP9-DL1 and increase the ratio of T cells 
to feeder cells for the flow-cytometry analysis. When all liquid was transferred to the filter/falcon 
the well was gently washed with 1ml PBS (PAN Biotech, Germany) without disrupting the layer 
of adherent cells, in order to remove all T cells lying loosely on the feeder cells. With another 1ml 
PBS the layer was destroyed and completely resuspended until no cell-clumps were visible any 
more. Additionally, 5ml were used to transfer the rest of the cells to the falcon. Finally, the well 
was rinsed with 10ml PBS. Before centrifugation the filter was squeezed -without damaging it – to 
press out the remaining drops. Then the sample was centrifuged 7min at 300 x g at 14 °C. After 
removing the supernatant, the cells were resuspended in 1ml of medium supplemented with 2ng/ml 
rhIL-7 and then counted (see 3.18). Finally after the analysis, the T-cells were reseeded to a well 
containing 1ml complete -MEM-media and OP9-DL1 feeder cells.  
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3.18 CELL COUNTING 
OP9-DL1 cells, T cells and monocytes were counted visually with a Neubauer improved counting 
chamber (Marienfeld, Germany). Trypan blue solution (Sigma-Aldrich, USA) was used to 
distinguish living cells from dead cells. The following formula was used to calculate the actual cell 
number: 
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 =




3.19 ANTIBODY STAINING FOR FLOW CYTOMETRY ANALYSIS 
For each time-point preferentially at least 50,000 monocytes / T cells or at least 10,000 CD34+ cells 
were harvested and stained. 
Only the monocytes samples were incubated 5min at room temperature with 1µl FC-block (BD 
Bioscience, USA) in 25µl flow-cytometry buffer previous to staining.    
The cells were washed with 1ml of flow-cytometry analysis buffer, centrifuged 5min at 300 x g 
and the whole supernatants removed.  The desired master-mix of antibodies was added and the 
samples were incubated in the fridge at 4 °C for 20min. Directly after staining the cells were washed 
again with 1ml flow-cytometry analysis buffer and then centrifuged. 1µl DAPI (Sigma-Aldrich, 
USA) in 1ml flow-cytometry buffer was used for this second washing step in some of the samples. 
After removing the supernatant the cells were resuspended in 270µl of flow-cytometry buffer and 
stored in the fridge or on ice till flow cytometry analysis. 
The time between staining and measurement was always within max. 3 hours. 
 
3.20 FLOW CYTOMETRY 
All flow cytometry measurements were performed either with the BD FACS CANTO II (BD 
Biosciences, USA) or the BD Accuri C6 (BD Biosciences, USA) devices. The software used for 
capturing was “DIVA” and the analysis were done with “Flow Jo”.  




3.21 FLOW CYTOMETRY ANALYSIS BUFFER 
Flow cytometry analysis-PBS (PAN Biotech, Germany) enriched with 0,1% 100 mg Sodium Azide 
(Sigma-Aldrich, Germany) and 1 mM EDTA (Sigma-Aldrich, Germany).  
 
3.22 DEPC WATER 
To clean the instruments used for RNA production, ddH2O is mixed with 1ml/l DEPEC (Sigma-
Aldrich, Germany). After 1 hour of swirling, the water is autoclaved. 
 
3.23 10X MOPS 
To obtain a 10x solution, 41.8 g MOPS (Thermo Fisher Scientific, Germany) was dissolved in 
400ml DEPC water. After the pH was adjusted to 7,0 using 1M NaOH, up to DEPC water was 
filled up to 700ml,  20ml DNAse- and RNAse-free 0,5 M EDTA (Promega, USA) together with 
20ml 1M sodium acetate (Thermo Fisher Scientific, Germany) were added as well. The final 
volume was adjusted to 1 l was by filling up with DEPC water. Subsequently the solution trough a 
0,45μm millipore filter. The complete 10x MOPS solution was wrapped in aluminium foil in order 
to keep protect from light and was kept at 4° in the fridge. 
mastermix for T cells staining mastermix for monocyte staining 
antibody fluorochrome company antibody fluorochrome company 
CD1α APC/Cy7 Biolegend CD4 PE-Cy7 eBioscience 
CD4 PE-Cy7 eBioscience CD14 PE-Cy7 BD Biosciences 
CD5 FITC Macs Miltenyi CD45 FITC Biolegend 
CD7 PerCP-CP5.5 BD Biosciences CD33 PerCP-Cy5.5 Biolegend 
CD8 AmCyan BD Biosciences CCR5 APC BD Biosciences 
CD34 PE BD Biosciences    
CCR5 APC BD Biosciences    
Table 5: List of antibodies used in the two different cell stainings 
 
32 
3.24 50X TAE BUFFER 
 242mg 80mM Tris base (AppliChem, Germany), 57,1ml 0,1% acetic acid (Sigma-Aldrich, 
Germany) and 100ml of 0,5M ethylendiaminetetraacetic acid (EDTA) (Sigma-Aldrich, Germany) 
were added to 700ml ddH2O. 
To remove undissolved salts a 0.45µm Millipore filter was used and finally the pH was adjusted to 
8.5 using dd H2O.  
 
3.25 6X ORANGE DYE  
40mg Orange G (Carl Roth, Karlsruhe, Germany), 3ml glycerol (Merck, Darmstadt, Germany) and 
a variable volume of ddH2O (Biochrom AG, Berlin, Germany) were mixed up to a final volume 






4.1 CORD BLOOD EVALUATION 
As starting material CD34+ cells derived from cord blood were isolated. The cord blood was kindly 
provided by the Frauenklinik of Freiburg after informed consent and ethics committee approval. 
Cell separation was performed by Ilona Skatulla, a technician of AG Cornu. After isolating the 
CD34+ cells, they were frozen and stored in liquid nitrogen. 
Before the stem cells could be seeded for either T cell differentiation or monocyte differentiation, 
a recovery period of 2 days in culture medium had to be carried out. The cells were evaluated via 
flow cytometry on day 0 (thawing) and day 2 (seeding for differentiation). Three different 
parameters were tested: CD34, CD38 and CCR5. CD34 and CD38 are known to be typical markers 
of HSCs in cord blood  (53). They are characteristic for this cell subset and can be therefore used 
to validate the starting material and the cells’ differentiation potency, too. As one aim has been to 
track CCR5 during the whole process of differentiation, the starting material had to be checked as 
well. CD34+ cells never showed any significant levels of CCR5 during the experiments. As there 
were no significant differences regarding surface markers, respectively CD34/CD38, (data not 
shown) in between these two time-points, day 2 was chosen for later evaluations. 
Figure 9 (A) shows the applied gating strategy. 91.5% of all events were clustered in a compact 
population (one experiment exemplarily shown). This population corresponds to the desired 
population. A viability staining with DAPI was performed to exclude dead cells and debris. To 
determine the “stemness” of the cells, CD34 and CD38 were monitored. These markers are 
characteristic for stem cells in early stages CD34+/CD38- cells are correspond to a very primitive 
subpopulation of CD34 cells. CD34 is lost early in the course of differentiation and therefore 
indicates an early progenitor in combination with a good stemness. As expected, hardly any CCR5 
co-receptor (1.76%) could be detected on the stem cells. 
99.7% (includes ± error bars values) of the cells which were seeded later had been positive for 
CD34.  Additionally 79.5% (includes ± error bars values) of all acquired cells had been both CD34 
and CD38 double positive. Figure 9 (A) shows an exceptional donor with only 2% CD34+/CD38- 

































Figure 9: Flow cytometry analysis of cord blood at day 2 after thawing. (A) The gate was set on the FSC and SSC 
parameters, CD34 and CD38 were detected in these cells. Panel 3 shows the amount of CCR5 on the surface of 




4.2 T CELL DIFFERENTIATION 
The differentiation of T cells was performed over a period of 4 weeks. In each week a staining with 
antibodies specific for several CD markers on the cells surface was carried out. The gating strategy 
for these stainings consisted of multiple gating strategy. As shown in (Figure 10 (B)) 5 stages of T 
cell development can be defined by their surface markers. Due to similar CD markers the stages of 
ISP and DP cells were fused into one stage: ISP/DP.  
Early T-progenitor (ETP) cells were defined as CD7 negative and CD34 positive. This subset was 
negative for CD5 and CD1α, too. T cell progenitor (Pro-T) cells were in comparison to ETPs 
positive for CD 7 and positive for CD34. In contrast to all cells in earlier stages Pre-T represented 
the first subset which had already lost CD34 on its surface. CD1α and CD5 were both found on 
Pre-Ts, but on Pro-Ts only CD 5 could be detected. Finally, a subset without CD34, CD7, CD5 
and CD1α was considered to represent immature single or immature double positive (ISP/DP) cells. 
The four different stages were monitored by the following gating strategy: initially the T cell 
population was gated and excluded from feeder cells using FSC and SSC parameters (Figure 10 
(A)). Within this population, the CD4/CD8 double negative cells were chosen, and subsequently 
analysed for the expression of CD34 and CD1a. This panel constitutes the basis for distinguishing 
different cell stages during the process of differentiation.  
In the course of 4 weeks, the proportion of the different subsets changed. The progress of 
differentiation is shown in Figure 10 (C) (one experiment is exemplarily shown). In week 1 ETPs 
and Pro-Ts represent the majority of cells. The second staining in week 2 showed a strong decrease 
of ETPs as well as of Pro-Ts. However, the subset of Pre-Ts increased in week 2. From week 3 on 
almost no ETPs could be detected. Also Pro-Ts declined strongly and were finally absent in week 
4. Pre-Ts could be monitored till week 4. The peak of Pre-Ts showed up in week 2 and from then 
on the numbers constantly decreased.   
According to the theoretical considerations the cells performed a cycling: each of the four weeks 
of differentiation showed a unique pattern. Young cells close to stem cells, especially seen at the 




Not only the proportion of the different subsets changed over time, but the overall size of the whole 
population changed as well (Figure 10 (D)): the longer the differentiation process lasted, the 
smaller the cells became. This fact refers to the well described cell sizes of stem cells and T cells. 
T cells are known to be small cells with a diameter of 7-8 µm. In contrast to T cells, stem cells are 
larger (54). The reduction of cell size during the process of in-vitro differentiation emphasizes its 
similarity to the physiological differentiation in-vivo: The in-vitro differentiated cells show the 













































week 1 week 2 week 3 week 4 
Figure 10: Schematic view on T cell differentiation and flow cytometry analysis of the T cell differentiation set up. 
Staining was performed weekly, the indicated surface markers where targeted via fluorescent antibodies. (A) Gating 
strategy, exemplary for week 2. OP9-mDL1 feeder cells were distinguished from all T cell progenitors by size in 
the first plot using the forward and side scatter. The CD4/CD8 double negative cells were selected and further 
monitored in terms of to CD34 and CD7.  In this panel four different types of subsets could be found. These subsets 
were subsequently proven by their characteristic phenotype. CD1α and CD5 were negative in both early T-
progenitors (ETP) (CD34+/CD7-/ CD5- /CD1α-) and immature single/double positive cells (ISP-DP). In T cell 
progenitors (pro-Ts) (CD34+/CD7+/ CD5+ /CD1α-) at least CD1 α and in T cell precursors (pre-Ts) (CD34-/low/ 
CD7+/ CD5+ /CD1α+) even both CD1α and CD5 were positive. (B) Overview of the four different stages of T cell 
precursors during physiological differentiation. Hematopoietic stem cells (HSC) differentiate into common 
lymphoid progenitors (CLP). In the thymus the cells reach further stages: early T-progenitors (ETP), T cell 
progenitors (Pro-Ts), T cell precursors (Pre-Ts) and immature single/double positive cells (ISP-DP). Finally they 
are exported from the thymus and become single positive cells (SP). (C) Subset analysis quantification and 
monitoring during 4 weeks of differentiation in (percentage of the whole population at each time point). In each 







4.3 CCR5 EXPRESSION DURING T CELL DIFFERENTIATION 
In order to evaluate which T-cell precursors are already targets for HIV, CCR5 was tracked during 
expressed on these immature T-cells. 
CCR5 expression was monitored in all 4 subsets described above during 4 weeks of differentiation. 
Figure 11 displays the quantification of the CCR5 expression on the subsets. In ETPs barely any 
CCR5 could be detected (5%) whereas in the Pro-T stage CCR5 was strongly expressed on the 
surface of the cells (21%). In both the Pre-T stage and the ISP-DP stage CCR5 surface expression 
could be detected to a similar extent:  29%.  
As indicated by the error bars the amount of detected CCR5 varied strongly between the different 
experiments. Material from three different donors in three independent experiments was used. The 
earliest stage of differentiation at which CCR5 could be detected was in between the stages of pro-
Ts and pre-Ts. Some donors’ cells expressed CCR5 already at the pro-T stage and others not until 

























Figure 11: Statistical analysis of CCR5 expression in T cell progenitors measured by flow cytometry of three 
independent experiments. The bars display the median CCR5 in four subsets with data from all time-points during 
the period of differentiation (4 weeks). 
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4.4 MONOCYTE/MACROPHAGE DIFFERENTIATION 
The differentiation of monocytes/macrophages was evaluated at two different time-points. In total 
4 different cytokines cocktails were compared: IL-3 alone, M-CSF alone, a combination of both 
IL-3 plus M-CSF and a condition named “change”. “Change” condition started with only M-CSF 
and after 5 days IL-3 was added to the cell culture. The first harvesting was carried out between 
day 10 and day 13. The second harvesting took place between days 16 to 19. In parallel to the T 
cell differentiation experiments the monocytes/macrophages were analysed via flow-cytometry.  
The gating strategy started with removing the debris by gating the cells by their size, further dead 
cells were excluded by a viability staining with DAPI. All living cells were analysed for CD33 and 
CD14. In CD33+/CD14- and CD33+/CD14+ cell populations both CCR5 and CD4 were monitored.  
The phenotype of pre-monocytes is pinpointed in Figure 12 (B): monoblasts are only CD45+, 
whereas pro-monocytes are CD45+ as well as CD33+. Almost mature monocytes can be found to 
be CD33+/CD14+ double positive. CD45 was not included in the antibody stainings because the 
focus laid on pro-monocytes and monocytes but not on monoblasts. 
Figure 12 (A) shows exemplarily media condition IL-3 at the first harvesting time-point. CD33+ 
single and CD33+/CD14+ double positive cells could be detected. In the double positive population 
CD4 and CCR5 were expressed on nearly half (48%) of the cells. The vast majority (77%) of all 
CD33+/CD14+ cells expressed CCR5. In contrast, barely any CD33+ single positive cells showed 
CCR5 and CD4 on their surface.  
Figure 12 (C) illustrates the comparison of the four different media conditions. Panel 1 shows the 
median of 3 independent experiments at the first time-point harvesting. IL-3 and IL-3+M-CSF in 
combination showed a similar distribution of CD33 single positive and CD33/CD14 double 
positive cells. Nevertheless, IL-3 in combination with M-CSF seemed to induce higher numbers of 
CD33/CD14 double positive cells than IL-3 alone (15.1% in IL-3 vs. 26.8% in IL-3+M-CSF (first 
time-point)). M-CSF had the greatest potential to achieve double positive cells (55.95% at first 
time-point; 58.35% at second time-point). As shown in Figure 12 (E) M-CSF impaired cell 
proliferation when compared to the other conditions. For this reason this condition was only carried 
out once and the “change” condition was established (which was also only evaluated once): In 
order to boost cell proliferation IL-3 was added to the “M-CSF only” condition after 5 days. This 
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condition could not generate the high percentage of double positive cells which has been observed 
in M-CSF alone (M-CSF: 1. Harvesting 56%, 2. Harvesting 58% vs. Change: 1. Harvesting 37%, 
2. Harvesting 34%). Nevertheless, the percentage of double positive cells was higher than in 
samples with IL-3 alone (IL-3: 1. Harvesting 15%, 2. Harvesting 30%).  
At the second harvesting time-point (Figure 12  (C)) a similar percentages of subsets for all media 
conditions could be found. The number of CD33/CD14 double positive cells was very similar in 
two media conditions except condition change. For IL-3 condition, the median of CD33+/CD14+ 
cells was 14.4% higher than in the first harvest, whereas it increased for M-CSF 2.4% and IL-3+ 
M-CSF 5.3%. Only in the condition change the median of double positive cells was 2.5% lower, 
but is not significant. 
A difference in terms of size of the total cell population was also observed during differentiation. 
Figure 12  (D) displays the size of the basic population determined by FSC/SCC at the first and 
second harvesting. The most differentiated cells appeared to be bigger than the less differentiated 
ones. Especially in the media containing M-CSF alone the mean of cells size was about 40% bigger 
than with IL-3 alone. Condition “change” has not been analysed regarding cell size.  
The total cell numbers were determined at the first harvesting time-point and shown in Figure 12 
(E). The starting material had been 60,000 cells for each condition. The first panel of (E) shows 
the starting cells number and total cell number at the first harvesting time-point, while the second 
panel displays the replication-factors, which indicate how often the cells have replicated till the 
harvesting time-point. To determine these factors, the cell number at the first harvesting time-point 
was divided by the initial number of cells.  
As M-CSF alone generated very low cell numbers in the first experiment, the media condition 
change was therefore established in the second experiment. The analysis of both media conditions 
do not include deviation graphs because both conditions have been tested only once. The data 
shown for the media conditions IL-3 and IL-3 + M-CSF includes two independent experiments. 
The media conditions containing IL-3 showed in both experiments a good yield: the median was 
962,500 cells. In the first experiment in which IL-3 + M-CSF was used the total number of cells 
was 1,625,000 and in the second experiment the number of cells was 800,000. The median for IL-
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3 + M-CSF was then 1,212,500. The total amount of cells with a number of 85,000 for the media 
condition M-CSF was rather low. The media condition change generated 825,000 cells.  
In conclusion all media conditions containing IL-3 provide an environment which supports cell 
proliferation. The direct comparison of IL-3 and IL-3+M-CSF shows a very similar potency to 
promote cell proliferation of both conditions. Possibly IL-3+M-CSF could even outperform IL-3 
alone. Nevertheless more experiments need to be done in order to specify the difference between 
these media conditions statistically. The fact that M-CSF alone shows a very poor ability to support 
cell proliferation is very obvious. For this reason the condition “change” has been established. 
Adding IL-3 to cultures with M-CSF only creates a boost of cell proliferation even at later time 
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Figure 12: Schematic view on monocyte differentiation and flow cytometry analysis of monocyte / macrophage 
differentiation setup in combination with statistical graphs of several independent experiments. Two time-points 
were chosen to harvest the cells and stain for macrophage / monocyte CD33+/CD14+ markers. (A) In panel 1 
the IL-3 condition at the first harvesting time-point is shown as an example. Dead cells were excluded with 
DAPI staining. Living cells were divided into CD33+/CD14- and CD33+/CD14+.  These subsets were further 
analyzed for CCR5 and CD4 expression. (B) Monitoring of monocyte differentiation: monoblasts (CD45+), 
pre-Monocytes (CD45+/CD33+) and monocytes (CD45+/CD33+/CD14+).  (C) Up to three different 
experiments were compared and plotted in order to choose the most efficient medium. The bars show the 
different distribution of subsets at either the first or the second time-point in each medium condition. (D) Cell 
size for each medium condition was monitored via flow cytometry at the first as well as at the second harvesting 
time-point using the forward scatter. The size is shown in two histograms, one for each time-point, displayed 
over each other. (E) All four different media were evaluated in terms of proliferation potential at the first 
harvesting. Shown are the total cell number at the first harvesting and the replication-factor which indicates 
how often the cells replicated. The grey bars in Panel 1 represent the starting material of proliferation with a 
number of 60,000 cells. In Panel 2 the replication factor is calculated: the total cell number at the time-point of 




4.5 CCR5 EXPRESSION DURING MONOCYTES/ MACROPHAGES DIFFERENTIATION 
Similar to the T cell differentiation analysis, the manifestation of CCR5 on the earliest 
differentiation stage of monocytes/macrophages was monitored.  
In all four media conditions a very similar result was displayed: CCR5 is highly expressed on 
CD33/CD14 double positive cells but hardly on CD33 single positive cells (see Figure 13). The 
plot shows the percentage of CCR5 in either CD33 or CD33/CD14 positive cells. A maximum of 
72% of the CD33/CD14 double positive cells expressed CCR5 on their surface in the “change” 
condition. On the opposite, only 15.7% CCR5, which was also the maximum detected for single 
positive cells overall, could be found on single positive cells in “change” condition. A difference 
of 56.3% between the two subsets strongly indicates that CCR5 is barely expressed on single 
positive cells, but well on double positive ones.  
 
  
Figure 13: Statistical analysis of CCR5 expression in monocyte/ macrophage progenitors measured by flow 
cytometry of three independent experiments for IL-3 and IL-3 M-CSF, two independent experiments for M-
CSF and one single experiment for change. The bars show the median CCR5 in either in CD33 single positive 
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In order to evaluate the nucleofection and simultaneously the efficiency of mRNA delivery and 
expression, cells were nucleofected with GFP mRNA.  
One day after nucleofection GFP treated cells were harvested and stained with DAPI. Figure 14 
(A) is representing flow cytometry data, three panels which depict the nucleofection-efficiency are 
shown. In the first panel the vital population of CD34+ cells based on forward and side scatter was 
selected. The gate of the second panel excludes all cell fragments and dead cells. Finally, in the 
third panel the GFP positive cells were gated. The mean percentage of living cells over three 
experiments was 84% (B). On the vast majority of the cells (98.8%, see Figure 14 (B)) a green 
fluorescence signal could be detected.  
The numbers above show that nucleofection was not only very efficient but also very well tolerated 




































Figure 14: Flow cytometry Analysis of CD34+ cells one day after nucleofection. (A) The first gate was set on 
the FSC and SSC, the second gate excludes dead cells and debris. In the third panel all cells captured by the 







4.7 T CELL DIFFERENTIATION OF MODIFIED STEM CELLS 
In 4.2 the results of the differentiation of untreated CD34+ stem cells derived from cord-blood was 
presented. In Figure 15 the comparison of untreated and TALEN treated cells is shown. 
CD34+ stem cells from cord blood were genetically modified before starting the process of 
differentiation. RNA of a right and a left TALEN were delivered to the cells by nucleofection. 
Analog to the TALEN treated cells, untreated cells from the same donor were differentiated 
following the same protocol.  
All four subsets identified above in 4.2 could be detected again in the graph of the edited cells (see 
Figure 15). Each corner of the square represents one particular subset. The percentage interval 
starts with 0% at the centre of the graph and ends with 80% at the outer square. Each week is 
represented by a different colour and a dot is drawn in each corner according to the percentage of 
the subsets. All dots are connected and a unique pattern is created. Every week is represented by 
one of these patterns. The graph reflects two independent experiments of two different donors.  
The characteristic cells for week 1 are the ETP. The percentage of this subsets is in the setup of 
untreated cells 12% and in the sample of treated cells 16%.  Pre-Ts, are compared to later weeks, 
barely present in week 1 (untreated: 14%; treated: 13%). The Pro-T cell subset is higher in the 
untreated (41%) than in the treated setup (27%). ISP-DP are either 31% in the untreated or 42% in 
the treated samples. 
Week 2 shows generally less ETP (untreated: 4%; treated: 7%) than week 1. Also the subset of 
Pro-T cells decreased. This subset is represented by 28% in untreated cells and 18% in treated cells. 
The subset distribution shifted and the greatest percentage of cells can be found in the Pre-T subset. 
In the untreated setup 55% of Pre-T cells and in the treated 54% were observed. ISP-DP decreased 
to 10% (untreated) and 18% (treated). 
The trend of an increasing number of Pre-Ts starting at week 2 continued in week 3. 67% of 
untreated cells and 60% of treated cells appeared to be Pre-T cells. From the third week on, ETP 
are hardly found anymore (untreated: 2%; treated: 2%). A decrease in percentage is observed in 
the subset of Pro-T cells. In the untreated setup this subset has 12% and in the treated setup 17%. 
Finally ISP-DP start increasing from this week on (untreated: 16%; treated: 17%). 
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In the last week (week4), there is almost a 50:50 distribution of Pre-T cells and ISP-DP. While the 
untreated setup shows 55% of Pre-T cells and 42% of ISP-DP, the treated setup shows 42% (Pre-
T) and 47% (ISP-DP). Both the subsets of ETP (untreated: 2%; treated: 3%) and Pro-T (untreated: 
2%; treated: 3%). 
This clearly demonstrate the shift of the subsets during differentiation, and that edited cells could 
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Figure 15: Differentiation subsets of untreated and genetically modified cells. The four corners represent the four 
subsets in the course of differentiation. For each week a dot representing the percentage of cells in this certain 
subsets is displayed. All dots are connected and a unique pattern is created which can be easily compared to 




4.8 MONOCYTE/MACROPHAGE DIFFERENTIATION OF MODIFIED STEM CELLS 
As done with the T-cell differentiation experiment, proof for a normally differentiation process of 
TALEN treated cells had to be performed as well.  
According to the results of the established differentiation protocol (see 4.4), the two conditions in   
which satisfying cell numbers could be assessed were chosen: IL-3 and IL-3 + M-CSF were used 
to check for the differentiation potential of CCR5 edited cells. In contrast to the established protocol 
in the direct comparison of untreated and treated cells, CD4 was also stained. As CD4 is highly 
necessary for HIV entry (see 1.2) the detection of CD33+/CD14+/CD4+ cells will be very 
informative. These cells represent the actual target cells of HIV. An untreated as well as a treated 
sample were kept at each condition in culture for 10 days.  
In the medium supplemented with IL-3 only, in both untreated and treated cells almost the same 
percentage of CD33+ cells was observed (untreated: 86%; treated: 90%). Less cells were CD33+ 
and CD14+ (untreated: 13%; treated: 9%). From these double positive cells in the untreated setup, 
70% were additionally CD4+ and 90% were CD4+ in the treated samples (see Figure 16). 
When IL-3+M-CSF were supplemented, 72% of the untreated and 94% of the treated cells were 
CD33+. 27% (untreated) and 6% (treated) could be found in the CD33+/CD14+ subset. Based on 
this subset in the untreated setup 58% and in the treated 61% were also CD4+.  
In the end both untreated as well as TALEN treated cells were able to differentiate into more mature 
cells. Treated cells showed not only the general ability of differentiation, they also showed a very 
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Figure 16: Analysis of monocyte/ macrophage development from flow cytometry data collected in two independent 
experiments. Each condition (IL-3 and IL-3 + M-CSF) is divided in an untreated and a treated setup. 3 populations 
are shown: CD33+, CD33+/CD14+ and based on the double positive subset CD33+/CD14+/CD4+. 
 
54 
4.9 CCR5 EXPRESSION IN MODIFIED AND UNTREATED T CELLS 
During the course of differentiation the CCR5 status was monitored at each measurement time-
point by flow cytometry analysis. Additionally to the staining which detects CCR5 on the cell 
surface and therefore reflects the phenotype, a test on the genomic level was performed.  Some of 
the cells were harvested, the DNA was extracted, CCR5 locus was amplified and a T7E1-Assay 
(see 3.10, Figure 8) was carried out. 
In contrast to the differentiation staining, CCR5 staining seemed to be very donor dependent. The 
level of CCR5 varied so strongly that it has not been possible to summarize the data in a statistical 
analysis.  
For both untreated and treated samples, the analysis on the surface expression of CCR5 was 
performed in the subset of all living cells. The flow cytometry data (Figure 17 (A)) showed that 
especially beyond week1, a higher number of CCR5 positive cells in the treated samples than in 
the untreated were present. At the beginning in week 1 the untreated setup showed 30% and the 
treated setup 32% of CCR5 positive cells. In week 2 the percentage of cells expressing CCR5 on 
their surface reached 12% in treated and 23% in untreated cells. Week 3 showed 7% of CCR5 
positive cells in the treated setup and 16% in the untreated one. Finally at the last measuring-point 
only 2% in the untreated and 4% in the treated setup could be detected to be CCR5 positive. 
The trend visible during the differentiation is a decrease of CCR5 positive cells as well in treated 
as in untreated cells. Generally a higher amount of CCR5 positive cells could be detected in the 
treated setup, which was not expected. 
Panel B of Figure 17 shows the genomic analysis of the CCR5 locus. Each week a treated sample 
was analysed along with a control of untreated cells which had not been nucleofected with TALEN 
mRNA. From week 1 to week 4 the untreated samples showed as expected only this one band. In 
samples modified by TALEN two fragments appeared on the gel. The intensity of this two bands 
in relation to the uncleaved top band indicated the percentage of cleavage. During the whole 
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Figure 17: Statistical analysis of CCR5 collected by flow cytometry and T7-Assay data. (A) Expression in untreated 
and TALEN targeted T cell progenitors measured by flow cytometry. The bars show the percentage of CCR5 in all 
living cells over the whole period of differentiation (4 weeks). (B) Gel of T-7 Assay performed on cells at each 
time-point for measurement. In each week a sample of untreated (UT) and TALEN treated cells (Tal) were analyzed 




4.10 CCR5 EXPRESSION IN MODIFIED AND UNTREATED MONOCYTES/ MACROPHAGES 
In parallel to the T cell differentiation, the CCR5 co-receptor was tracked in the monocyte/ 
macrophage experiment. In contrast to the T cells, only one measuring point was chosen (see 4.4) 
and two different conditions in the differentiation protocol were used. 
In the first panel of Figure 18 (A) the percentage of CCR5 in three different subsets is plotted. This 
first subset consists of all living cells (dead cells and debris were excluded). From all living cells 
either all CD33 single positive or all CD33/14 double positive cells were analyzed. 
In the samples with IL-3 only 4% (untreated) and 2% (treated) of CCR5 positive cells were found. 
CD33+ cells showed a low CCR5 in both untreated (2%) and treated (1%) samples. The highest 
percentage of CCR5 could be found in the CD33+/CD14+ cells. 25% of these double positive but 
untreated cells expressed CCR5 on their surface. In the setup of genetically modified cells, 11% of 
CCR5 positive cells were observed.  
When IL-3+M-CSF was supplemented to the medium, 11% of the untreated cells and 2% of the 
treated cells showed a CCR5 surface expression. In the CD33 subset the CCR5 was detected on 
2.3% of the untreated and on 1.6% of the treated cells. Again the highest number of CCR5 positive 
cells was found in the CD33+/CD14+ subset. 39% of all untreated double positive cells and 17% of 
all treated double positive cells were found to be CCR5 positive. 
DNA of cells grown in each condition (IL-3 only and IL-3+M-CSF) was harvested and analysed. 
In both samples the TALEN mRNA treated cells showed a significant cleavage of more than 80% 
while the untreated controls did not show any cleavage at all (see Figure 18 (B)). 
Contrary to the T cell experiment for the monocyte/macrophage differentiation the flow cytometry 
data harmonized with the T7E1-Assay. Both analysis described a reduction of CCR5 in cells 
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Figure 18: Analysis of CCR5 collected by flow cytometry and T7-Assay data. (A) CCR5 expression in untreated 
and TALEN targeted monocyte/ macrophage progenitors measured by flow cytometry. The bars show the 
percentage of CCR5 in all living cells over the whole period of differentiation (4 weeks). (B) Gel of T-7 Assay 





As mentioned in project goals (2), after the first step of establishing a differentiation protocol the 
second step was to address the question whether genetically modified stem cells retain their 
physiological differentiation potential and can differentiate to target cells.  
 
5.1  CORD BLOOD EVALUATION 
The amount of nearly 80% CD34 and CD38 double positive cells in a population of stem cells 
isolated from umbilical cord blood has been observed before. Almost the same distribution of CD 
markers as shown in chapter 4 was found by L.Chan et. al. - although they extracted these cells for 
other purposes (55). The high expression of CD38 together with CD34 is characteristic for healthy 
haematopoietic stem cells and indicates the potential of these cells to differentiate in either myeloid 
or lymphoid lineage (56), whereas the smaller proportion of CD34+ CD38- cells represent a more 
primitive stem cells subpopulation. Figure 9 shows that CCR5 is not expressed on cord blood 
derived stem cells. The percentage of 1.76% CCR5 positive cells is negligible and could possibly 
be background from an unspecific staining reaction.   
 
5.2 T CELL DIFFERENTIATION 
The gating strategy shown in Figure 10 initially excluded all CD4/CD8 double positive cells 
because T cell progenitors are known to neither express CD4 nor CD8. Cells cannot be 
differentiated into CD4 or CD8 positive cells within a period of one or two weeks.  
The general ability to differentiate CD34+ stem cells into precursors of T cells is shown in Figure 
10. The cells performed a cycling from CD34+/CD7- to CD34+/CD7+ to CD34-/CD7+ and finally 
to CD34-/CD7-, corresponding to the transition from ETP to ISP-DP cells. Most of the cells in one 
subset underwent this cycling synchronically, that is why the subset of Pro-Ts shows high numbers 
in week 2: Pro-Ts from week 1 moved on in the process of differentiation and could therefore be 
found in the subset of Pre-Ts at week 2. Nearly all Pro-Ts had become Pre-Ts and the subset of 
Pro-Ts decreased in week 2.  
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Additionally to the tracked CD markers, the average cell size within the lymphocyte population 
(Figure 10 (D)) gives a hint for the differentiation stage. The antibody stainings strongly suggest a 
greater number of differentiated cells in week 3 and 4. This finding is supported by the greater cell 
size observed in week 4 contrary to week 1. Early blood cells appear larger due to high transcription 
and translation activities whereas more mature cells and direct T-cell precursors are known to be 
small cells.  
Contrary to the expectation of gaining ISP-DPs earliest at late time-points of in-vitro 
differentiation, some of these cells were already present in week 1. As some of these ISP-DPs were 
negative for all other stained markers the explanation for this observation is that certain cells are 
blocked in early stages of differentiation. These cells do not express any of the monitored CD 
markers on their surfaces. In week 2 the blocked cells disappear which causes the decline of ISP-
DPs at this time-point (Figure 10 (C)). The cells detected in the ISP-DSP subset in week 1 are not 
truly ISP-DPs cells. On the contrary, chances are high that the detected cells in the ISP-DP subset 
in week 3 and 4 were what they had been expected to be: cells in a differentiation stage close to 
single positive T cells.  
Another explanation for high numbers of ISP-DPs in week 1 is that within an inhomogeneous 
sample of CD34+ stem cells some T cell precursors of high differential stages were already present. 
These cells were ISP-DPs at week 1 but then died at week 2 due to the lack of sufficient ligands 
for mature T cells. 
In fact, single positive T cells (CD4 or CD8) could never be detected. Starting at week 4 the cell 
number began to decrease. At harvesting point week 5 (not shown in the figure) almost no T cells 
could be found anymore. The speculation is that some specific factors might be missing at this 
time-point in order to generate mature T cells. Another possible explanation is that the premature 
cells are somehow blocked in their stages. In a T cell differentiation in-vitro study S. Hoseini et. al 
(43) showed a similar finding: immature T cells were blocked in vitro at the Pre-T cell stage. 
The speed of the differentiation process varied between the donors. This indicates that there are 
inter-individual differences in the differentiation potential of stem cells. One donor’s population 
showed Pre-Ts already in week 2 (Figure 10), another donor’s cells could reach this stage not 
before week 3 (data not shown).  
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CCR5 is detectable on the cells’ surface for the first time between the Pro-T and Pre-T stage. The 
percentage of CCR5 on ETPs is comparable to the starting material of CD34+ stem cells which 
show no expression of CCR5 on their surface at all. Donor specific variations could be found: in 
one experiment, the Pro-T cells already highly expressed CCR5 and in another experiment CCR5 
was found earlier in Pre-T cell. These inter-individual differences cause the high standard deviation 
shown in Figure 10 (A). In conclusion, all stages before the Pro-T stage are not targetable for HIV 
in terms of CCR5. Apart from CCR5, the CD4 receptor is mandatory for HIV to enter cells, too.  
Although CCR5 can be monitored in the generated T cell precursor, these cells are, due to the lack 
of CD4, no target cells for HIV. Only T cells expressing both CCR5 and CD4 can actually be 
infected by the virus: mature T cells. Nevertheless, the data shows that CCR5 is present already at 
early time-points during the differentiation of T cells. 
In chapter 5.5 below, the differentiation potential of genetically modified stem cells is evaluated in 
detail. The experiments demonstrated that CCR5 edited CD34+ cells can undergo the same 
maturation process as untreated cells. This ability of a sufficient and natural differentiation 
constitutes the basis of a functional therapy with ex-vivo treated stem cells.  
 
5.3 MONOCYTE/ MACROPHAGE DIFFERENTIATION 
All of the four tested media conditions described in 4.4 had the potential to generate CD33/CD14 
double positive cells (Figure 12). Although the ratio of single positive to double positive cells 
strongly varied among donors.  
M-CSF alone showed the best yield of double positive cells but the differentiated cells hardly 
proliferated.  The low cell number caused the high standard deviation in Figure 12 and Figure 13. 
Therefore the media condition containing M-CSF only was not very useful to generate many 
monocyte/ macrophage precursors. By introducing condition “change” the importance of IL-3 for 
proliferation was clearly visible. In order to show the differentiation of modified CD34+ cells into 
macrophages/monocytes via flow cytometry and molecular biologic methods, a sufficient number 
of cells was needed. Therefore only the media conditions IL-3 + M-CSF and IL-3 could be used as 
culturing conditions for this purpose. 
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CCR5 was already detected at the first harvesting time-point.  Figure 13 (A) shows that the earliest 
time point for CCR5 to be expressed is in CD33/CD14 double positive cells.  About 50% (Figure 
12 (B)) of these double positive cells were theoretically targets for HIV: these cells were both CD4 
and CCR5 positive. In contrast to the T cell protocol (in which CCR5/CD4 positive cells could not 
be detected) the monocyte differentiation protocol showed the potential to produce HIV targets. 
These target cells could be used in the future for functional assays such as for example viral 
challenges. 
Contrary to the size distribution observed during T cell differentiation, more differentiated 
monocytes/macrophages showed a greater size than in earlier differentiation stages. Unlike T cells, 
monocytes and especially macrophages are known to be large cells. Although haematopoietic 
precursor cells are highly active in transcription, translation and protein synthesis, mature 
monocytes/macrophages show a larger cell diameter. HSCs have a diameter of 12µm, the size of 
monocytes and macrophages is 15-20µm (36). Additionally to the size analysis, a microscopic 
evaluation of the nucleus could have been performed. Cells with a strong protein synthesis have a 
big nucleus (36). More differentiated cells are less active in protein translation and the nucleus is 
expected to be smaller. 
 
5.4 NUCLEOFECTION 
Though the concept of nucleofection invented by Amaxa (distributed by Lonza) claims to be more 
efficient and less toxic to the cells than other electroporation methods, some toxic effects, 
especially slower cell growth, can still be observed (57). Dr. Giandomenico Turchiano from AG 
Cathomen has performed several experiments to optimize nucleofection-program for CD34+ 
primary cells. Each of these programs differ in the applied electric pulses. In many cases the high 
transfection efficiency of a program was linked to a great loss of viability. As mentioned in 
“material and methods” I decided to use the program DZ-100. According to Dr. Turchianos results 
this program was able to combine a good efficiency and high viability. Nevertheless, as presented 
in Figure 14 one day after nucleofection some toxic effects could be observed. At 24h post 
nucleofection, the viability staining performed via flow cytometry analysis showed toxicity, as well 
as directly looking at the cells through a light microscope confirmed that the cells underwent great 
stress. Instead of round and chubby, the cells had irregular-shaped membranes and appeared 
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ragged. Nevertheless the efficiency of mRNA delivery was highly satisfying and the viabilities 
improved over time, as the cells recovered. The control cells (see Figure 14) nucleofected with 
GFP mRNA internalized the mRNA and started producing GFP with efficiencies close to 100%. 
As a clear population with a strong green signal could be detected one can assume that also the 
TALEN RNA was delivered with similar efficiency to the target cells. 
 
5.5 T CELL DIFFERENTIATION OF MODIFIED STEM CELLS 
During differentiation both setups (untreated vs. TALEN treated) underwent the same cyclic 
expansion and decreasing of subsets. The untreated as well as the TALEN treated cells showed 
ETP only in week 1, a high number of  Pro-T cells in week 1 and week 2 and an increase of Pre-T 
cells from week 2 to week 3 which then dropped in week 4 in favor of ISP-DP. 
The percentage of each untreated and treated subsets especially differed mainly in the first and 
already less in the second week. From the third week on, the development and the percentage of 
subsets was more or less identical. This trend can be summarized as following: the later the week 
the more similar the treated sample became to the untreated. The explanation for this trend is that 
the nucleofection triggered great stress to the stem cells. Also, the internalization of mRNA might 
have had a negative influence on the cells: in fact, the control cells nucleofected with GFP mRNA 
showed some stress as well. Pulsing the cells without mRNA also stresses the cells, albeit to a 
lesser degree (not shown). So the combination of pulse and mRNA delivery increased toxicities. 
Nevertheless a certain amount of time was needed for recovery. Already at week 2 the negative 
effect of the nucleofection seemed to vanish. In week 1 the percentage of ETP was a little bit higher 
in the treated (16%) than in the untreated (12%) setup. This fact was complemented by the number 
of Pro Ts. Untreated cells were able to give rise to 41% Pro-T cells already in week 1. The TALEN 
mRNA nucleofected cells instead showed only 26% Pro-T cells (see Figure 15). As ETP represent 
the direct progenitors of Pro-T cells this lead to the conclusion that nucleofected cells were just a 
little bit slower than the untreated controls. As previously mentioned, this reflects a period of 
recovery where the cells seemed to deal more with cell repair mechanisms than with differentiation. 
Another hint as of why the subset-percentages in week 1 and 2 showed a deviation, is the absolute 
cell number. Although more cells (120,000 vs. 100,000) were used for the nucleofection setup than 
for the untreated one, after nucleofection the cell number was lower in the treated sample (due to 
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the nucleofection toxicity). In order to minimize cell manipulation this was not determined by the 
nucleocounter but by eye via the light microscope. As not only the cytokines in the medium but 
the cellto cell interactions do play an important role in T-cell differentiation (58), the concentration 
of cells likely influences the potential of differentiation. As the toxic effect was decreasing over 
time and also the cell numbers became more equal between untreated and treated till week 4, the 
percentage of subsets became more similar.   
The similar distribution of cells in the different subsets at week 4 indicates that in fact CCR5 knock-
out cells are able to differentiate into T cell precursors. It might be necessary to find a less stressful 
way for mRNA delivery and further improve the pulses in order to enhance the differentiation 
potential of the stem cells already from the beginning. Further efforts have been put toward these 
improvements in the lab.  
 
5.6 MONOCYTE/ MACROPHAGE DIFFERENTIATION OF MODIFIED STEM CELLS 
When comparing untreated and treated CD34+ stem cells after 10 days in IL-3 more CD33+ cells 
are found in the treated setup than in the untreated one (see Figure 12). This observation is true for 
IL-3 as well as for M-CSF. In this condition the difference (=22%) between untreated and treated 
appeared even more clearly. To understand this, one has to consider the percentage of the 
CD33+/CD14+ subset. On the contrary more double positive cells formed here from the untreated 
stem cells than from the genetically modified ones. Again, especially if both (IL-3 + M-CSF) 
supplements were used the difference was even more convincing (IL-3: 4%; IL3+M-CSF: 21%). 
Condition IL-3 and M-CSF had the potential to produce more CD33+/CD14+ double positive cells. 
Similar to the T cell differentiation, nucleofected cells seemed to be a little bit slower in 
differentiation. The higher percentage of CD33+ single positive in the treated cell setup in 
combination with a lower percentage of the CD33+/CD14+ double positive subset reflects this fact. 
The theory, that a certain recovery time is needed after the nucleofection, is also applicable for the 
differentiation in monocytes/macrophages. 
Interestingly, treated stem cells show a higher percentage of CD33+/CD14+/CD4+ cells than 
untreated. As there were more CD33+/CD14+ positive cells in the untreated setup there were as 
well more cells somewhere in between CD33+/CD14+ and CD33+/CD14+/CD4+. This idea is based 
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on the concept that if one cell once started the differentiation this cell efficiently moves on the 
triple positive stage. The more cells are performing this development the more cells can be detected 
somewhere between the stages. These cells might appear still in a lower subset though on the move 
to a higher one.  
Additionally, the absolute cell number may give an explanation as well. The samples derived from 
TALEN targeted cells had always a lower cell number than the untreated controls. There might be 
some block by the CD4 cells for other cells to become CD4+, too. Especially in the IL-3 + M-CSF 
condition where more CD33+/CD14+ cells were found than with IL-3 only, were less CD4+ cells 
were detected. As the size and therefor the volume of the wells were kept the same with each 
sample, a higher absolute number of CD4+ cells (in the TALEN treated sample) would have also 
raised the concentration of “blocking ligands”. This theory of course assumes that the culturing 
dish reflects a microenvironment which regulated its cell composition independently.  
Directly compared, both conditions with IL-3 only and IL-3+M-CSF showed similar results. In 
terms of the ability to generate triple positive (CD33+/CD14+/CD4+) cells treated with IL-3 only 
seemed to work slightly better in both treated and untreated cells. In the untreated cells the IL-3+ 
M-CSF condition gave rise to 14% more double positive (CD33+/CD14+) cells than IL-3 alone. In 
samples with TALEN targeted cells, a difference between both conditions was hardly to determine 
(except triple positive cells). If a functional assay is planned and target cells for HIV in are required, 
because of the better yield of CD4+ cells, Il-3 only condition would probably the condition to be 
favoured. In order to assess the differentiation potential of stem cells both media conditions are 
equally efficient.  
  
5.7 CCR5 IN MODIFIED AND UNTREATED T CELLS & MONOCYTS/ MACROPHAGES 
Both Figure 17 and Figure 18 show a sufficient modification of the differentiated cells on the 
genomic level. 
In the T cell differentiation experiment the percentage of cleaved CCR5 was in week 1, 3 and 4 
higher than 75%. The lower percentage of cleavage in week 2 was probably caused during the 
evaluation process and not by the genotype of the cells (Figure 17). The most probable explanation 
is that while loading the gel some DNA was spilled. This theory corresponds to the fact that not 
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only the two cleaved bands are lower in intensity but also the upper uncleaved band seems to be 
weaker in comparison to the bands of week 1, 3 or 4.  
The T7E1-Assay performed from samples of monocyte/macrophage precursors show an even 
higher percentage of cleavage in the gel. 83% of cleavage in cells of samples with the 
supplementation of IL-3 only and even 97% of cleavage in cells grown in a medium with IL-3 and 
M-CSF was detected.  
As mentioned before (see 3.10) the evaluation of the T7E1-Assay gels was performed with a 
software which analyses the pictures of the gel and calculate the density of the pixels. Although a 
ratio between uncleaved and cleaved bands is calculated, the saturation of the gel image plays an 
essential role. As the gels were not exposed for exactly the same time under UV light, slight 
differences of saturation are likely to be found. Additionally a bias during the analysis of the 
pictures by using a software may have occurred. The calculations of ImageJ are not fully 
automated. Although each measurement has been performed three times, each user can chose 
different parameters and settings in the software. Therefore the concrete number of cleavage-
percentage has to be evaluated carefully. Also, resolution of T7E1-Assay lies in the 5% range, 
therefore variation within this range are expected. Nevertheless the overall trend is clearly visible: 
CD34+ edited stem cells keep their genotype during the differentiation towards their final cell type. 
This data strongly suggests that the mature cells will remain stably modified.  
Theoretically, if the CCR5 co-receptor gene is knocked out, the surface expression level of CCR5 
protein on the targeted cells should be reduced. A hypothetical genomic knockout of 100% would 
then as well lead to a 100% reduction of surface CCR5, whereas a more realistic 90% KO would 
give rise, according to a statistical distribution of the alleles, to 81% of biallelic mutations, 18% of 
monoallelic mutations and a remaining1% of wt cells. The cells carrying the monoallelic mutation 
will still be able to express CCR5 from the wt allele, albeit to a lesser degree, but still theoretically 
allowing HIV to enter the cell. Considering the Indels length as random, 1/3 of these events will 
correspond to an insertion or deletion that will not disrupt the CCR5 reading frame. This was 
confirmed by deep sequencing data (collected by Markus Hildenbeutel AG Cathomen).These 
findings mean that the mRNA of the protein is transcribed and if this new mRNA is stable, 
translation takes place as well. Surely, this modified CCR5 co-receptor is not identical with the 
wild type but depending on where the mutation occurred it might be still sufficient to reach the 
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membrane and for an antibody or even HIV to bind. To reduce this chance the coding sequence of 
the N-terminal region was chosen as TALEN target, thus promoting a truncation of the protein 
right at the beginning after the first 10 amino acids. The target region codes for several tyrosines 
and acidic amino acids which are used as binding region by HIV, (34). Also, the antibody chosen 
for the CCR5 staining was specific for this region. 
Although the 3A9 clone which was used as antibody, binds to an epitope identically to the deleted 
region, C. Königs et. al (59) mentioned that this clone has the potential to slightly bind to other 
regions as well, such as the extracellular loop 1 and 3 of the CCR5 protein.  
The fact that CCR5 expressing cells are still found in both TALEN treated stem cells derived T 
cells and monocytes/ macrophages, might be based on the factors mentioned above: the CCR5 co-
receptor is still expressed as some of the deletions caused by the TALEN are not completely 
abrogating protein expression. The protein fragment on the surface exhibits structures to which the 
antibody binds and a signal is detected in the flow cytometry analysis. This does not necessarily 
mean that the mutated CCR5-coreceptor can be used for HIV entry efficiently, but it does also not 
proof the opposite.  
The explanation for a high number of CCR5 positive cells in the T cell precursor setup, especially 
in the treated compared to the untreated cells, might be caused by a weak point of the 3A9 clone. 
A cross reactivity of this clone between CCR5 and CCR8 is described (60). As CCR8 is reported 
to be involved in inflammatory events (61), this receptor could be potentially upregulated in T cell 
precursors due to the stress caused by the nucleofection and the mRNA. As 
monocytes/macrophages are part of a completely different cell lineage (lymphoid vs. myeloid) 
CCR8 might not be expressed in these cells to the same extend. CCR8 was found on a special T 
cell subset of CD4+ and CD8+ T cells as well as on monocytes and especially on dendritic cells. 
On the surface of CD8+ T cells CCR8 is strongly upregulated after T cell activation (62). Although 
no CD8+ cells could be detected in my differentiation experiment (data not shown) it is not 
impossible that already precursor T cells have the potential to upregulate CCR8. 
Ideally the staining for CCR5 should be linked with the simultaneous detection of CCR8. In this 
way the signal could be clearly assigned. Because of the lack of time I was not able to set up an 
experiment to address this question. As my goal was to show the differentiation potential of 
TALEN treated stem cells this matter was of second priority.  
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5.8 FURTHER EXPERIMENTS 
The experiments which I have reported showed that CD34+ stem cells derived from cord blood are 
indeed able to differentiate in vitro. Progenitors of the final cell type keep their genomic status: the 
cleavage observed in the stem cells persisted until the final stages which were observed in this 
artificial differentiation. This fact indicates that also the patient who is treated with CCR5 knock-
out stem cells, will potentially be able to obtain mature cells from these transplanted stem cells. In 
the patient organism, the fully differentiated cells will ideally still carry the mutation in the CCR5 
gene. 
Apart from the genomic characteristics also the phenotype of the T cell and monocyte/ macrophage 
precursors was analysed. In the monocyte/macrophage experiment a reduced CCR5 expression 
compared to the control was not only deducted from the T7E1-Assay but also via flow cytometry. 
Although reduced, some CCR5 signal could still be detected on the cell surface. As discussed in 
5.7 this might not truly be a signal of CCR5 but could also represent CCR8. In order to sort out 
this observation as well as the contradictory results of the CCR5 staining on T cell progenitors a 
new round of differentiation should be started in which CCR5 and CCR8 are simultaneously 
tracked. In this way more definitive information about the phenotypic receptor status can be 
acquired. 
The next step after in-vitro differentiation is a verification in mice. Are the transplanted cells able 
to engraft? Will the host immune system accept these new cells? Are CCR5 knock-out cells able 
to persist constantly in a foreign organism? Some hints to answer this questions were already given 
by Li et al. in 2013. In NOD.Cg-PrkdcscidIL2rgtm1WJI/SZJ (NSG) mice ZFN-treated haematopoietic 
stem cells were transplanted and an engraftment of the CD34+ could be observed. Also, 
descendants of the transplanted stem cells like CD4+ and CD8+ T cells, B cells and monocytes 
could be found in these mice (63). This data proves that the concept of modified stem cells 
engrafted in foreign hosts is valid. Not only stem cells treated with ZFN, but also cells treated with 
TALEN should be able to show engraftment. Indeed, mice experiments performed in our lab 
indicate that engraftment and differentiation are possible, as well as stable genomic disruption. 
Before moving forward to a clinical application, functionality assays have to be performed. The 
knowledge that genomic engineered and transplanted stem cells can differentiate physiologically 
is of course only useful if the modification has been successful. At the moment in the Cornu lab 
 
68 
functional assays with pseudotyped lentiviral vectors and wt HIV have been performed on 
terminally differentiated edited CD4+ cells, derived from peripheral blood. Functional assays for 
edited stem cells are still missing: a challenge with HIV to address the question whether the CCR5 
knockout is sufficient to trigger entry inhibition of the virus. Ideally CD33+/CD14+/CD4+ 
monocyte/macrophage precursors are sorted by flow cytometry and isolated. These cells closely 
represent actual HIV target cells. After isolation, the target cells will be challenged with either a 
lentiviral vector which acts as surrogates for HIV-1 and is pseudotyped with the R5 tropic HIV 
glycoprotein and expresses the marker protein GFP, or directly challenge the cells with the actual 
wt HIV virus.  
Additionally, instead of in-vitro differentiation approach, the mouse model needs to be evaluated. 
Mice with engrafted CD34+ stem cells carrying high knockout-rates in the CCR5 gene will be 
challenged with the virus itself. Facilities that perform this kind of experiment are not available in 
Germany. Both challenges will prove if the reduction of CCR5 is high enough to establish a 
sufficient immunity against HIV. 
Every drug has its specific side effects. In the case of designer nucleases off-target events are 
considered as side effects. Sequences similar to the actual target might be cleaved by the used 
TALEN as well. As long as these off-targets appear in unimportant parts of the genome no negative 
effects will be observed. If however tumor suppressor genes are harmed, severe consequences can 
be caused to the patient. For the pair of TALEN I have used, one off-target was found in an intron. 
After verifying this off-targets by deep sequencing again in the cells from the mouse model it will 
be verified if clonal expansion has taken place, although this is a process that might require years, 







Today’s therapy of HIV offers patients the opportunity to live almost normally. The life expectancy 
of HIV patients increased dramatically over the last decades. Nowadays patients are hardly 
restricted in their way of life. Although side effects under ART are still present, a new therapy in 
order to be revolutionary needs to finally cure HIV. This remaining task is targeted by many new 
therapy concepts including genome engineering. A broader distribution of drugs as well as a better 
education on HIV and safe sex are both able to decrease HIV incidence and mortality worldwide, 
but after all the curative therapy will remain the last resort. 
Designer nucleases such as TALEN and CRISPR/Cas9 are highly promising tools to solve the 
riddle of curing HIV. The efficiency of CCR5 knock-out introduced by TALEN, is already very 
high. The off-target activity is rather low and the risk of severe or even lethal side effects seem to 
be minimal. In my studies I set up protocols for the in-vitro differentiation for both T cells and 
monocytes/makrophages. Additionally I produced and then delivered TALEN mRNA to CD34+ 
stem cells derived from cord blood and proved that if designer nucleases are applied to these stem 
cells, they are able to differentiate physiologically. I obtained CD33+/CD14+/CD4+ monocyte/ 
macrophage precursors as well as direct T cell progenitors. Especially the monocyte/ makrophage 
precursors represent actual target cells for HIV and can be used for further functional analysis. 
Moreover, I have been able to demonstrate that once established in stem cells, the knock-out 
remains throughout the whole process of differentiation and persists very likely in the finally 
differentiated mature cells, too. The cleavage efficiencies I observed in the CCR5 locus, ranged 
between 70% and 97%. This indicates that almost all cells were efficiently genetically modified. 
After the protocol for a TALEN based genomic treatment of CD34+ stem cells was introduced and 
optimized by Emily Meyer in the Cornu lab, I further proved in my studies that the concept of 
genome engineering HIV target cells by editing their stem cells is at least functional in-vitro. This 
data strongly suggests that the transplanted cells in human are able to support the patient’s organism 
in develooping immune cells. The next experiments will have to deal with the issue of in vivo cell 
differentiation. Furthermore functionality assays have to be performed which show that the concept 
of CCR5 knock-out cells is valid and really sufficient in inhibiting HIV to infiltrate the organism. 





Seit den Anfängen der HIV Therapie hat sich die Behandlung der Patienten insbesondere in den 
letzten Jahrzehnten stark weiterentwickelt, HIV positive Patienten haben heutzutage weder in ihrer 
Lebenserwartung noch ihrer Lebensführung mit drastischen Einschränkungen zu rechnen. 
Dennoch ist es auch heute noch nicht möglich HIV infizierte Patienten vollends zu heilen. Hier 
müssen die neuen Therapieoptionen, so auch die Gentherapie, ansetzen. Maßnahmen zur 
Aufklärung über „safe sex“ und HIV, sowie die verbesserte Verteilung von Medikamenten 
insbesondere in Drittweltländer sind in der Lage die Inzidenz und Prävalenz der HIV Infektionen 
weltweit zu beeinflussen. Ultima ratio wird aber auch weiterhin die Heilung der Erkrankung 
bleiben, die nur mit Hilfe neuer kurativen Verfahren realisiert werden kann. 
Designer Nukleasen wie TALEN oder CRISPR/Cas9 stellen vielversprechende Werkzeuge im 
Kampf gegen HIV dar. Die Eliminierung des CCR5 co-receptors, der eine wesentliche Rolle für 
die Infizierung der Zelle durch HIV darstellt, auf genomischer Ebene lässt sich mit TALEN effektiv 
durchführen. Ungewünschte „off-targets“ (akzidentiell modifizierte Regionen die nicht der 
Zielregion entsprechen) werden selten beobachtet. Auch die Wahrscheinlichkeit für toxische 
Nebenwirkungen erscheint niedrig. Im Rahmen meiner Dissertation konnte ich Protokolle für die 
in vitro Differenzierung von CD34+ Stammzellen aus Nabelschnurblut in sowohl Monozyten/ 
Macrophagen als auch T-Zellen etablieren. Des Weiteren ist es mir gelungen TALEN mRNA zu 
produzieren und diese in die Zellen einzuschleusen, um dann zu zeigen, dass genetisch modifizierte 
Stammzellen ihr physiologisches Differenzierungspotential während dieses Procedere behalten. 
Die T-Zell Vorläufer und insbesondere die CD33+/CD14+/CD4+ Monozyten/Macrophagen gelten 
als direkte Zielzellen von HIV im menschlichen Organismus. Ergänzend zur Analyse des 
Differenzierungspotentials zeigen meine Ergebnisse, dass die Zielzellen ihren, im 
„Stammzellalter“ veränderten, genetischen Status während der Reifung zur erwachsenen Zelle 
beibehalten. Die knock-out Effektivität im CCR5 locus lag in meinen Experimenten bei mindestens 
70% und maximal 97%, diese Zahlen belegen: so gut wie alle Stammzellen sind erfolgreich 
genetisch verändert worden. 
Basierend auf Emily Meyers Erkenntnissen zum erfolgreichen „genome editing“ mittels TALEN 
in CD34+ Stammzellen in der AG Cornu (33), habe ich mit meiner Arbeit gezeigt, dass zumindest 
in vitro das Konzept zur genetischen Modifikation von HIV Zielzellen über die Bearbeitung deren 
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Stammzellen funktional ist. Auf Grund dieser Daten kann vermutet werden, dass auch modifizierte 
Stammzellen, die in den menschlichen Organismus transplantiert wurden, in der Lage sind, 
funktionsfähige Blut- und Immunzellen zu produzieren. Zukünftige Experimente werden sich mit 
dieser in vivo Differenzierung beschäftigen müssen. Außerdem muss in einem kontrollierten 
Umfeld überprüft werden, ob die in den Zellen etablierte Modifikation tatsächlich den erhofften 
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